abt-199 profile

venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	49846579
CHEMBL ID	3137309
CHEBI ID	133021
SCHEMBL ID	523816
SCHEMBL ID	19236295
MeSH ID	M0583124

Synonym
abt 199
gdc 0199
abt199
CHEBI:133021 ,
venetoclax
1257044-40-8
4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-n-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
abt-199
venclexta
HY-15531
CS-1155
NCGC00345789-01
gdc-0199
n54aic43pw ,
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((3-nitro-4-((tetrahydro-2h-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
rg7601
benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
rg-7601
unii-n54aic43pw
venetoclax [usan:inn]
venetoclax [mi]
venetoclax [inn]
venetoclax [orange book]
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((3-nitro-4-((tetrahydro-2hpyran-4-ylmethyl) amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
venetoclax [who-dd]
venetoclax [usan]
venetoclax [jan]
MLS006010298
smr004701366
SCHEMBL523816
CHEMBL3137309
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
venetoclax (jan/usan/inn)
D10679
venclexta (tn)
AKOS025289539
venclyxto
gtpl8318
AC-28754
FT-0699586
DTXSID30154863 ,
J-005269
mfcd23160052
EX-A168
bdbm60828
us9174982, 369
bdbm189459
us9174982, 5
HMS3653J06
NCGC00345789-10
abt-199 (gdc-0199)
2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-n-(3-nitro-4-((tetrahydro-2h-pyran-4-yl)methy
venetoclax; abt-199
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1h-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
SW219672-1
bdbm50162774
venetoclax(abt-199)
DB11581
NCGC00345789-11
SCHEMBL19236295
BCP06811
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
venetoclax (abt199)
S8048
KS-1470
4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-n-[(3-nitro-4-{[(oxan-4-yl
4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-n-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
)methyl]amino}phenyl)sulfonyl]-2-[(1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
Q23671272
SB16499
4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-n-[[3-nitro-4-[[(tetrahydro-2h-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-n-[[3-nitro-4-[[(tetrahydro-2h-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)-
AMY343
HMS3745E07
CCG-270543
NCGC00345789-05
2-((1h-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
A850921
venetoclax (abt-199)
4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
nsc766270
nsc-766270
EN300-7399830
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1h-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
abt-0199
dtxcid0077354
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((3-nitro-4-(((oxan-4-yl)methyl)amino)phenyl)sulfonyl)-2-((1h-pyrrolo(2,3-b)pyridin-5-yl)oxy)benzamide
4-(4-((4'-chloro-5,5-dimethyl(3,4,5,6-tetrahydro(1,1'-biphenyl))-2-yl)methyl)piperazin-1-yl)-n-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzene-1-sulfonyl)-2-((1h-pyrrolo(2,3-b)pyridin-5-yl)oxy)benzamide
venetoclaxum
l01xx52
Z2037279542

Excerpt	Reference	Relevance
" The safety analyses of the adverse events (grade 3 or higher) of neutropenia and infection indicated that higher average venetoclax concentrations were not associated with an increase in adverse events."	( Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Awni, WM; Eckert, D; Freise, KJ; Humerickhouse, RA; Jones, AK; Mensing, S; Salem, AH; Wong, SL, 2017)	0.46
" With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase."	( Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Kaur, V; Swami, A, 2017)	0.46
" Results All patients (48/48) completed the single ascending dose, 25 continued into the multiple ascending dose, and 44/50 completed the multiple ascending dose; two of the withdrawals (venetoclax 60 mg and 600 mg cohorts) were due to adverse events."	( Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Black, K; Clarke, SH; Curtis, C; Desai, M; Fleischmann, R; Grebe, KM; Ignatenko, S; Lu, P; Medema, JK; Stolzenbach, J; Wong, SL; Zeng, J, 2018)	0.74
" Logistic regression, time-to-event, and progression-free survival (PFS) analyses were used to evaluate the relationship between venetoclax exposure, NHL subtype and response, PFS, or occurrence of serious adverse events."	( Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Freise, KJ; Gopalakrishnan, S; Menon, RM; Mensing, S; Parikh, A; Salem, AH; Verdugo, ME, 2018)	0.48
" We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact of dosing modifications in routine clinical practice."	( Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Allan, JN; Bailey, N; Barr, PM; Brander, DM; Cheson, BD; Coombs, CC; Dorsey, C; Eyre, TA; Fox, CP; Goy, A; Hill, BT; Jacobs, R; Kabel, C; Kirkwood, AA; Lamanna, N; Lansigan, F; Mato, AR; Morse, H; Muralikrishnan, S; Nabhan, C; Pagel, JM; Pearson, L; Rhodes, J; Roeker, LE; Schuh, A; Schuster, SJ; Shadman, M; Shah, NN; Singavi, AK; Sitlinger, A; Skarbnik, AP; Tuncer, HH; Ujjani, CS; Williams, AM; Winter, AM; Yazdy, M, 2019)	0.51
" Grade 3 adverse events included mucositis, diarrhea, and liver transaminitis (n = 3 each)."	( Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM, 2021)	0.62
" Therefore, this study was designed to investigate the toxic effect of VTX on the heart."	( Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-κB and BCL-2 Pathway. AlAsmari, AF; Alasmari, F; Alghamdi, A; Alharbi, M; Ali, N; Almeaikl, MA; Alqahtani, F; Alsaleh, N; AlSwayyed, M; Alyousef, MK; Hakami, HM, 2022)	0.72
" The clinical course passed safely without the occurrence of unexpected adverse events during the administration of crushed venetoclax tablets in combination with azacitidine."	( Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia. Fujita, N; Kameoka, Y; Kitadate, A; Kobayashi, T; Miura, M; Nara, M; Sato, H; Takahashi, N; Yamashita, T; Yoshioka, T, 2022)	0.72
"VEN-containing regimens could be suggested as effective and safe treatments to RR MM patients with t(11;14) or high BCL-2 levels."	( Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. He, F; He, W; Hu, H, 2023)	0.91
" The most common adverse events were neutropenia and thrombocytopenia."	( Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Bond, D; Boonstra, P; Carty, SA; Danilov, AV; Herrera, AF; Kaminski, MS; Kandarpa, M; Karimi, YH; Kump, K; Maddocks, K; Mayer, TL; Nachar, V; Nikolovska-Coleska, Z; Phillips, TJ; Popplewell, L; Takiar, R; Wilcox, RA, 2023)	0.91
"Novel therapies improve clinical outcomes in chronic lymphocytic leukemia (CLL), although adverse event (AE) profiles differ."	( Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL). Castriota, F; Chang, R; DerSarkissian, M; Duh, MS; Gu, Y; Guo, H; Kunzweiler, C; Patel, H; Ryan, KJ; Wahlstrom, SK, )	0.13
"8%) and gastrointestinal adverse events (34."	( Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Amaya, M; Bosma, G; Gutman, JA; Kent, A; Marciano, K; McMahon, C; Pollyea, DA; Rezac, R; Schwartz, M; Smith, CA; Tobin, J, 2023)	0.91
" The aim of this systematic review and meta-analysis was to evaluate the efficacy and adverse events of Venetoclax combined with hypomethylating agents (HMAs) for AML/MDS relapse post-transplantation."	( Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Du, Y; Li, C; Liu, Y; Yan, J; Zhang, C; Zhao, Z, 2023)	0.91
" Overall response rates (ORR), stringent complete response rates (sCR), complete response rates (CR), very good partial response rates (VGPR), partial response rates (PR), stable disease (SD), progressive disease (PD) and adverse events were synthesized using either a random-effects model or a fixed-effects model."	( Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis. Gao, X; Li, Y; Sun, F; Wu, H; Yan, M; Zeng, H; Zhang, G; Zhao, X, 2023)	0.91
"This study indicates that venetoclax alone or in combination with other agents reveals favorable treatment responses and acceptable adverse events in treating RRMM."	( Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis. Gao, X; Li, Y; Sun, F; Wu, H; Yan, M; Zeng, H; Zhang, G; Zhao, X, 2023)	0.91

Excerpt	Reference	Relevance
" The terminal half-life in cancer subjects was estimated to be approximately 26 h."	( Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. Agarwal, SK; Freise, KJ; Humerickhouse, RA; Jones, AK; Salem, AH; Wong, SL, 2016)	0.43
" Pharmacokinetic parameters were estimated using noncompartmental methods."	( Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. Agarwal, SK; Dunbar, M; Enschede, SL; Humerickhouse, RA; Salem, AH; Wong, SL, 2017)	0.46
"Eleven patients had evaluable pharmacokinetic data and were therefore included in the statistical analyses."	( Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Agarwal, SK; Chien, D; Danilov, AV; Gutierrez, M; Hu, B; Lewis, LD; Puvvada, S; Salem, AH; Wong, SL, 2017)	0.46
" Since similar increases in exposure were observed for both enantiomers, even though CYP2C9 is only involved in the metabolism of the S-enantiomer, and the half-life of both enantiomers remained the same, the interaction does not appear to be mediated via CYP2C9."	( Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Agarwal, SK; Freise, KJ; Hu, B; Salem, AH; Sidhu, DS; Wong, SL, 2017)	0.46
"The objectives of the analysis were to develop and verify a venetoclax physiologically based pharmacokinetic (PBPK) model to predict the effects of cytochrome P450 3A (CYP3A) inhibitors and inducers on the PK of venetoclax and inform dosing recommendations."	( Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Freise, KJ; Salem, AH; Shebley, M, 2017)	0.46
" Here, we review the available literature on the pharmacokinetic and pharmacodynamic properties of these novel agents to guide the reader in the appropriate use of ibrutinib, idelalisib, and venetoclax."	( Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. Hill, BT; Waldron, M; Winter, A, 2017)	0.46
" The study shows that the pharmacokinetic profile of venetoclax in CLL patients with the 17p deletion is comparable to the overall CLL as well as non-Hodgkin's lymphoma patient populations."	( Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Agarwal, SK; Dunbar, M; Salem, AH, 2017)	0.46
" The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to mechanistically describe absorption and disposition of an amorphous solid dispersion formulation of venetoclax in humans."	( Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story. Borchardt, TB; Bow, DAJ; Carr, RA; Castleberry, S; Emami Riedmaier, A; Hall, JA; Lindley, DJ; Nijsen, M; Slade, RT; Stuart, P, 2018)	0.48
" To elucidate on-target and pharmacodynamic effects of acalabrutinib, we evaluated several laboratory endpoints, including proteomic changes, chemokine modulation and impact on cell migration."	( Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG, 2018)	0.48
" Non-compartmental and population pharmacokinetic analyses of venetoclax serial plasma concentrations were conducted."	( Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Medema, JK; Minocha, M; Othman, AA; Zeng, J, 2018)	0.48
"In female subjects with SLE, venetoclax displayed pharmacokinetic characteristics consistent with previous observations in subjects with hematologic malignancies."	( Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Medema, JK; Minocha, M; Othman, AA; Zeng, J, 2018)	0.48
" Venetoclax half-life and time to maximum concentration remained relatively unchanged when administered with azithromycin."	( Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Agarwal, SK; Bueno, OF; Menon, RM; Salem, AH; Tong, B, 2018)	0.48
" Pharmacokinetic parameters were estimated using non-compartmental methods."	( Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Agarwal, SK; Bueno, OF; Dave, N; Hu, B; Marbury, T; Menon, RM; Miles, D; Salem, AH, 2019)	0.51
" Here, we aimed to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics (PK) using physiologically based pharmacokinetic (PBPK) and population PK modeling."	( Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis. Brackman, DJ; Menon, RM; Mukherjee, D; Salem, AH; Suleiman, AA; Zha, J, 2023)	0.91
"Following the decade-long clinical investigation, venetoclax has accrued pharmacokinetic (PK) data across multiple populations and widely ranging demographics, intrinsic, and extrinsic factors."	( Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials. Deng, R; Gong, JQX; Menon, R; Mensing, S; Salem, AH; Suleiman, AA, 2023)	0.91

Excerpt	Reference	Relevance
" ABT-199 synergized strongly, however, when combined with dinaciclib and with other drugs affecting MCL1, including standard DLBCL chemotherapy drugs."	( Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Kendrick, SL; Li, L; Park, S; Persky, DO; Pongtornpipat, P; Puvvada, SD; Rimsza, LM; Schatz, JH; Tiutan, T, 2015)	1.56
"Western blots and real-time RT-PCR were used to determine levels of Mcl-1 after ABT-199 treatment alone or in combination with cytarabine or daunorubicin."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.89
"Our results demonstrate that sequestration of Bim by Mcl-1 is a mechanism of intrinsic ABT-199 resistance and supports the clinical development of ABT-199 in combination with cytarabine or daunorubicin for the treatment of AML."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.89
" ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220."	( Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling. Elmi, L; Graham, A; Grundy, M; Hall, M; Jones, T; Pallis, M; Russell, N; Seedhouse, C, 2018)	1.39
" Our data provide a landscape of drug combination effects in BL and suggest that targeting CDK and BET could provide a novel vulnerability of BL."	( Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. Brors, B; Huber, W; Hüllein, J; Kurilov, R; Lee, KS; Lukas, M; Oleś, M; Sellner, L; Tomska, K; Wagner, L; Walther, T; Zenz, T, 2018)	0.48
" In addition, VU661013 was safely combined with venetoclax for synergy in murine models of AML."	( A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Arrate, MP; Ayers, GD; Boyd, KL; Fesik, SW; Fischer, MA; Fuller, L; Gorska, AE; Hogdal, LJ; Lee, T; Olejniczak, ET; Ramsey, HE; Savona, MR; Sensintaffar, J; Strickland, SA, 2018)	0.48
" High remission rate and low early mortality combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for older adults not suitable for intensive chemotherapy."	( Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Agarwal, S; Chyla, B; Enjeti, A; Fakouhi, KM; Fiedler, W; Hayslip, J; Hong, WJ; Hou, JZ; Humerickhouse, R; Lee, S; Lin, TL; Popovic, R; Roboz, GJ; Salem, AH; Savona, M; Strickland, SA; Tiong, IS; Walter, RB; Wei, AH; Xu, T, 2019)	0.51
"Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab."	( A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Allan, JN; Bailey, N; Barr, PM; Bhavsar, EB; Brander, DM; Cheson, BD; Coombs, CC; Dorsey, C; Eyre, TA; Fox, CP; Goodfriend, JM; Goy, AH; Hill, BT; Jacobs, R; Kennard, K; Kirkwood, AA; Lamanna, N; Lansigan, F; Mato, AR; Muralikrishnan, S; Nabhan, C; Pagel, JM; Rhodes, J; Roeker, LE; Schuh, A; Schuster, SJ; Shadman, M; Shah, NN; Singavi, AK; Sitlinger, A; Skarbnik, AP; Tuncer, H; Ujjani, CS; Weissbrot, H; Williams, AM; Winter, AM; Yazdy, MS; Zelenetz, A, 2019)	0.51
" The objectives of the current analysis of observed data from adult patients randomized to venetoclax-rituximab in the phase III MURANO study were to characterize venetoclax pharmacokinetics (PKs) using a Bayesian approach, evaluate whether a previously developed population PK model for venetoclax can describe the PKs of venetoclax when administered with rituximab, and to determine post hoc estimates of PK parameters for the exposure-response analysis."	( Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Agarwal, P; Boyer, M; Deng, R; Ding, H; Freise, KJ; Gibiansky, L; Girish, S; Humphrey, K; Kater, AP; Kshirsagar, S; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Salem, AH; Seymour, JF; Wang, J, 2019)	0.51
" The updated model was used to describe venetoclax PKs after repeated dosing in combination with rituximab, and to determine post hoc estimates of PK parameters for exposure-response analysis."	( Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Agarwal, P; Boyer, M; Deng, R; Ding, H; Freise, KJ; Gibiansky, L; Girish, S; Humphrey, K; Kater, AP; Kshirsagar, S; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Salem, AH; Seymour, JF; Wang, J, 2019)	0.51
"The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacitidine or decitabine] or low-dose cytarabine [LDAC])."	( Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH, 2019)	0.51
"We retrospectively reviewed the efficacy and safety of venetoclax combined with chemotherapy for patients with R/R T-ALL treated at our institution."	( Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Alvarado, Y; Borthakur, G; Bose, P; Jabbour, E; Jain, N; Kantarjian, H; Kebriaei, P; Konopleva, M; Ohanian, M; Rausch, CR; Ravandi, F; Richard-Carpentier, G; Rytting, M; Savoy, JM; Short, NJ; Yilmaz, M, 2020)	0.56
" Venetoclax at a median dose of 200 mg/d for 21 days, generally with a concomitant azole antifungal, was combined with various agents, including hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), asparaginase, nelarabine, decitabine, or other intensive chemotherapy."	( Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Alvarado, Y; Borthakur, G; Bose, P; Jabbour, E; Jain, N; Kantarjian, H; Kebriaei, P; Konopleva, M; Ohanian, M; Rausch, CR; Ravandi, F; Richard-Carpentier, G; Rytting, M; Savoy, JM; Short, NJ; Yilmaz, M, 2020)	0.56
" These targeted therapies could be more tolerable than classical antineoplastics, but potential drug-drug interactions (DDI) are relatively frequent."	( Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A, 2020)	0.56
"We recommend the "venetoclax + HMAs combined with dose-adjusted CAH/HAG" regimen as an effective treatment for adult R/RAML."	( Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports. Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B, 2020)	0.56
" Parameter optimization, guided by sensitivity analyses, was conducted such that the models could replicate clinical exposures of posaconazole and drug-drug interactions with sensitive CYP3A substrates including venetoclax."	( Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach. Bhatnagar, S; Gibbs, JP; Menon, RM; Miles, D; Mukherjee, D; Salem, AH, 2021)	0.62
" Outcomes in patients with spliceosome mutations treated with hypomethylating agents in combination with venetoclax (HMA+VEN) remains unknown."	( Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Alvarado, Y; Borthakur, G; Chien, K; Daver, N; DiNardo, CD; Furudate, K; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, MY; Lachowiez, CA; Loghavi, S; Maiti, A; Montalban-Bravo, G; Ohanian, M; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Yilmaz, M, 2021)	0.62
"In this first-in-human study of the pan-BET inhibitor mivebresib as monotherapy (MIV-mono) or in combination with venetoclax (MIV-Ven), the safety profile, efficacy, and pharmacodynamics of mivebresib were determined in patients with relapsed/refractory AML (ClinicalTrials."	( A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Aldoss, I; Borthakur, G; Chen, C; Jonas, BA; Joshi, RH; Modi, DA; Odenike, O; Popovic, R; Prebet, T; Rizzieri, DA; Wolff, JE, 2021)	0.62
"Mivebresib was tolerated and showed antileukemic effects as monotherapy and in combination with venetoclax in patients with relapsed/refractory AML."	( A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Aldoss, I; Borthakur, G; Chen, C; Jonas, BA; Joshi, RH; Modi, DA; Odenike, O; Popovic, R; Prebet, T; Rizzieri, DA; Wolff, JE, 2021)	0.62
" This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in ND-AML and R/R-AML."	( Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M, 2021)	0.62
" Venetoclax has been proved to be effective for R/R CLL as a single agent or in combination with various regimens."	( Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis. Bai, Y; Peng, P; Tang, X; Zou, W, 2022)	0.72
"Venetoclax in combination with rituximab (VEN + R) demonstrated prolonged overall survival (OS) and progression-free survival (PFS) for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in comparison to standard chemoimmunotherapy [bendamustine + rituximab (BR)]."	( Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. Barbier, M; Bennison, C; Durno, N; Knapp, C; Örtli, M; Schwenkglenks, M, 2022)	0.72
" We present population pharmacokinetics (PopPK) and exposure-response (ER) analyses for venetoclax (a selective BCL-2 inhibitor) administered with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with relapsed/refractory (R/R) and previously untreated (1L) non-Hodgkin lymphoma (NHL) from the phase 1b/2 CAVALLI study, to confirm dose selection for future studies."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.72
"Analyses included 216 patients with R/R or 1L NHL treated for eight 21-day cycles with 400-800 mg venetoclax (cycle 1: days 4-10; cycles 2-8: days 1-10) in combination with R for eight cycles and CHOP for 6-8 cycles."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.72
"The PopPK and ER analyses, in addition to the positive benefit-risk observed in the clinical data, support the selection of 800 mg venetoclax given with R-CHOP for future studies in BCL-2-immunohistochemistry-positive patients with 1L DLBCL."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.72
" Recent studies have shown that venetoclax combined with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) may have a good effect on these patients."	( Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Kuang, P; Liu, T; Qin, Y, 2023)	0.91
" We demonstrated the synergism of [Bis + ABT199/venetoclax] in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells."	( Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B, 2022)	0.72
" Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve patients unfit for intensive induction."	( Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Babushok, DV; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Graveno, ME; Hexner, EO; Loren, AW; Luger, SM; Mangan, BL; Martin, ME; McCurdy, SR; Nietupski, R; Perl, AE; Porter, DL; Pratz, KW, 2022)	0.72
" The novel regimen of venetoclax (VEN) combined with hypomethylating agents (HMAs) has a synergistic therapeutic effect and a tolerable safety profile, which has been officially approved by the US Food and Drug Administration (FDA) for newly diagnosed AML in adults who are 75 years or older or patients precluding intensive induction chemotherapy."	( Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases. He, J; Liu, F; Wang, N, 2022)	0.72
"Venetoclax combined with intensive chemotherapy has been shown to be safe with promising activity in fit patients with newly diagnosed acute myeloid leukaemia."	( Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Borthakur, G; Daver, N; DiNardo, CD; Furudate, K; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Lachowiez, CA; Loghavi, S; Maiti, A; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Shpall, E; Takahashi, K; Xiao, L; Yilmaz, M, 2022)	0.72
"Venetoclax combined with intensive induction chemotherapy induced deep MRD-negative remissions, allowing transition to allogeneic HSCT in first remission, and improvement in event-free survival."	( Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Borthakur, G; Daver, N; DiNardo, CD; Furudate, K; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Lachowiez, CA; Loghavi, S; Maiti, A; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Shpall, E; Takahashi, K; Xiao, L; Yilmaz, M, 2022)	0.72
"Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia (AML)."	( Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C, 2022)	0.72
"This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy."	( SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Bertoni, F; Buske, C; Ceriani, L; Dirnhofer, S; Eckhardt, K; Forestieri, G; Hayoz, S; Hess, D; Hiddemann, W; Hitz, F; Hohloch, K; Kienle, DL; Krasniqi, F; Mach, N; Mey, U; Moccia, AA; Novak, U; Pott, C; Rossi, D; Sartori, G; Schär, S; Schmidt, C; Stathis, A; Unterhalt, M; Zucca, E, 2022)	0.72
" A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA + VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML."	( Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M, 2022)	0.72
"The purpose of this study was to identify the incidence, sites and main pathogens, and risk factors for infectious complications occurring in patients with adult acute myeloid leukemia (AML) during the first course of venetoclax combined with decitabine or azacitidine."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"A retrospective cohort analysis was performed of 81 patients with AML older than 14 years who received the first cycle of venetoclax combined with a hypomethylating agent (HMA) between March 2018 and March 2021 at our institution."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"Compared with conventional chemotherapy, the incidence of infectious complications of venetoclax combined with decitabine or azacitidine significantly decreased."	( A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX, 2022)	0.72
"Using individual patient-level data from the phase 3 VIALE-A trial, this study assessed the cost-effectiveness of venetoclax in combination with azacitidine compared with azacitidine monotherapy for patients newly diagnosed with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, from a United States (US) third-party payer perspective."	( Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. Chai, X; Downs, L; Iantuono, E; Ma, E; Montez, M; Nie, X; Pratz, KW; Xie, J; Yin, L, 2022)	0.72
"Venetoclax in combination with intensive therapies is explored in both the upfront and relapse/refractory (R/R) setting, and available data suggest that such regimens are effective albeit with added hematological and infectious toxicity."	( Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Amit, O; Apel, A; Bar-On, Y; Frisch, A; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shargian, L; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M, 2022)	0.72
"Venetoclax in combination with nucleoside analogs such as hypomethylating agents (HMA) and low-dose cytarabine (LDAC) has led to unprecedented response and survival outcomes in patients with acute myeloid leukemia (AML)."	( Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Ball, BJ; Koller, PB; Pullarkat, V, 2022)	0.72
"Venetoclax in combination with obinutuzumab has significantly improved efficacy versus immunochemotherapy (progression-free survival) in patients with chronic lymphocytic leukaemia who have not received prior treatment."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
"Venetoclax in combination with obinutuzumab was shown to be a dominant alternative compared to the rest of the treatment alternatives, with a lower cost per patient (€-67,869 compared to chlorambucil in combination with obinutuzumab, €-375,952 compared to ibrutinib, €-61,996 compared to fludarabine in combination with cyclophosphamide and rituximab, and €- 77,398 compared to bendamustine in combination with rituximab)."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
"Venetoclax in combination with obinutuzumab is an efficient and dominant alternative for treating previously untreated patients with chronic lymphocytic leukaemia compared to the available alternatives and from the perspective of the Spanish National Health System."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
"Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance mediated by various mechanisms, including BCL-2 mutations."	( Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Deng, J; Fang, DD; Fu, C; Li, N; Tang, Q; Wang, Q; Xue, SL; Yang, D; Yin, Y; Zhai, Y; Zhang, K; Zhou, F, 2023)	0.91
" The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine (Ven+Aza) for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude using IC."	( Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis. Au, Y; Bui, CN; Chai, X; Guinan, K; Lachaine, J; Mathurin, K; Schuh, AC, 2022)	0.72
" Venetoclax is a selective BCL-2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia."	( 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study. Jiang, L; Jin, J; Lang, W; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Tong, H; Xu, G; Xu, W; Yang, H; Ye, L; Zhou, X; Zhu, H, 2023)	0.91
" We report the first case of primary PCL successfully treated with upfront novel agents consisting of Venetoclax and daratumumab in combination with intensive chemotherapy and allogeneic transplantation."	( Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation. Ahmad Asnawi, AW; Chong, SL; Koh, AZY; Lau, NS; Liew, PK; Md Fauzi, A; Selvaratnam, V; Tan, SM; Tang, ASO, 2023)	0.91
" All patients received venetoclax in combination with either a hypomethylating agent or conventional chemotherapy."	( Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Aaronson, K; Agrawal, AK; Braun, BS; Golden, C; Huang, BJ; Marinoff, AE; Michlitsch, J; Southworth, E; Stieglitz, E; Thrall, A; Vo, KT, 2023)	0.91
"Venetoclax in combination with hypomethylating agents or cytotoxic chemotherapy was effective in a subset of pediatric/AYA patients with advanced hematologic malignancies, but multiple severe infections were observed, particularly among patients who received venetoclax in combination with chemotherapy."	( Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Aaronson, K; Agrawal, AK; Braun, BS; Golden, C; Huang, BJ; Marinoff, AE; Michlitsch, J; Southworth, E; Stieglitz, E; Thrall, A; Vo, KT, 2023)	0.91
"To investigate the efficacy and safety of venetoclax (VEN) combined with demethylating agents (HMA) in the treatment of relapsed/refractory acute myeloid leukemia (R/R AML)."	( [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia]. Bian, MR; Huang, SL; Lin, GQ; Si, YJ; Wan, Y; Wang, L; Wang, Y; Zhang, B; Zhang, XX; Zhang, YM, 2023)	0.91
"VEN combined with HMA is an effective salvage therapy for patients with R/R AML and is well tolerated by patients."	( [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia]. Bian, MR; Huang, SL; Lin, GQ; Si, YJ; Wan, Y; Wang, L; Wang, Y; Zhang, B; Zhang, XX; Zhang, YM, 2023)	0.91
" The aim of this systematic review and meta-analysis was to evaluate the efficacy and adverse events of Venetoclax combined with hypomethylating agents (HMAs) for AML/MDS relapse post-transplantation."	( Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Du, Y; Li, C; Liu, Y; Yan, J; Zhang, C; Zhao, Z, 2023)	0.91
"This study demonstrated a moderate benefit of Venetoclax in combination with HMAs for patients with relapsed AML/MDS post-transplantation (including those who have received prior HMAs therapy), and may become one of treatment options in the future."	( Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Du, Y; Li, C; Liu, Y; Yan, J; Zhang, C; Zhao, Z, 2023)	0.91
"Venetoclax (VEN) in combination with intensive chemotherapy (IC) is increasingly used to treat patients with high-risk acute myeloid leukemia (AML)."	( Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M, 2023)	0.91
" We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events."	( Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm. Fujita, J; Hirose, Y; Kamimura, R; Kiyohara, E; Nagate, Y; Nakaya, A; Nojima, S; Shibayama, H, 2023)	0.91
"This study aimed to evaluate the efficacy and safety of venetoclax in combination with hypomethylating agents and CAG (VEN-DCAG) regimens in patients with relapsed/refractory acute myeloid leukemia (R/R AML)."	( Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Jing, Y; Li, Y; Liu, Y; Yu, Z; Zhang, R, 2023)	0.91

Excerpt	Reference	Relevance
" Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199."	( ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Ackler, SL; Boghaert, ER; Catron, ND; Chen, J; Dayton, BD; Ding, H; Elmore, SW; Enschede, SH; Fairbrother, WJ; Huang, DC; Humerickhouse, RA; Hymowitz, SG; Jin, S; Khaw, SL; Kovar, PJ; Lam, LT; Lee, J; Leverson, JD; Maecker, HL; Marsh, KC; Mason, KD; Mitten, MJ; Nimmer, PM; Oleksijew, A; Park, CH; Park, CM; Phillips, DC; Roberts, AW; Rosenberg, SH; Sampath, D; Seymour, JF; Smith, ML; Souers, AJ; Sullivan, GM; Tahir, SK; Tse, C; Wendt, MD; Xiao, Y; Xue, JC; Zhang, H, 2013)	2.04
" While these properties are associated with low oral bioavailability (F), both navitoclax and ABT-199 showed moderate F in preclinical species."	( The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Boggs, J; Catron, ND; Choo, EF; Jenkins, G; Lubach, JW; Souers, AJ; Voorman, R; Zhu, C, 2014)	0.83
" In 2014, several new compounds were approved for patients with ultrahigh risk genetic factors (17p-, TP53mut) and for relapsed/refractory CLL: both idelalisib and ibrutinib are orally bioavailable kinase inhibitors that block key regulators of central pathways."	( [Chronic lymphocytic leukemia: current standards and novel approaches]. Stilgenbauer, S; Tausch, E, 2014)	0.4
" Two studies evaluated the relative bioavailability of venetoclax in healthy subjects: (1) a bioequivalence study to compare the bioavailability of the film-coated tablet with that of an earlier uncoated tablet and (2) a food effect study to evaluate the effect of food on venetoclax pharmacokinetics."	( Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. Agarwal, SK; Chien, D; Dunbar, M; Freise, KJ; Nuthalapati, S; Salem, AH; Wong, SL, 2016)	0.43
" Taken together, our results suggest that inhibition of mitochondrial metabolism by Metformin or Phenformin is associated with increased leukemia cell susceptibility to induction of intrinsic apoptosis, and provide a rationale for clinical studies exploring the efficacy of combining biguanides with the orally bioavailable derivative of ABT-737, Venetoclax."	( Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Andreeff, M; Bornmann, W; Duque, JE; Enciso, L; Jaramillo, D; Konopleva, M; Krystal, G; Lee, JT; Lopez, C; Morales, L; Pan, R; Samudio, I; Suarez, M; Velez, J, 2016)	0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
" A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor."	( Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Anderson, MA; Davids, MS; Desai, M; Dunbar, M; Gerecitano, JF; Gordon, GB; Gressick, L; Humerickhouse, RA; Kahl, BS; Kim, SY; Kipps, TJ; Pagel, JM; Peale, F; Puvvada, S; Roberts, AW; Ross, JA; Salem, AH; Seymour, JF; Verdugo, M; Wierda, WG; Zhu, M, 2017)	0.46
" It is an orally bioavailable small molecule that binds BCL2 very specifically."	( Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Huang, DCS; Roberts, AW; Seymour, JF; Stilgenbauer, S, 2017)	0.46
"Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy."	( Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Hessler, P; Idler, KB; Lam, LT; Leverson, JD; Park, CH; Rapp, LR; Smith, ML; Tahir, SK, 2017)	0.83
" Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects."	( Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. Chen, HJ; Cox, PB; DeGoey, DA; Wendt, MD, 2018)	0.48
"Venetoclax, an orally bioavailable inhibitor of BCL-2, was approved in 2016 by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) patients with 17p deletion [del(17p)], who have received at least one prior therapy."	( Venetoclax for the treatment of chronic lymphocytic leukemia. Bossio, S; Caruso, N; De Stefano, L; Gentile, M; Martino, M; Morabito, F; Palummo, A; Petrungaro, A; Recchia, AG; Storino, F; Uccello, G; Vigna, E, 2017)	0.46
" Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia."	( Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018)	0.48
" Voruciclib, an orally bioavailable clinical stage CDK-selective inhibitor, potently blocks CDK9, the transcriptional regulator of MCL-1."	( Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Beirne, E; Burns, C; Casalini, JR; Deckwerth, TL; Dey, J; Ditzler, SH; Dixon, CP; Gillespie, KC; Grenley, MO; Kerwin, WS; Kleinman, EF; Klinghoffer, RA; Merrell, AJ, 2017)	0.46
" Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion."	( Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Agarwal, S; Choi, M; Chyla, B; Coutre, S; Davids, MS; Eradat, H; Furman, RR; Heffner, L; Humerickhouse, RA; Jones, JA; Potluri, J; Verdugo, M; Waskiewicz, T; Wierda, WG; Zhou, L, 2018)	0.48
" The estimates (95% bootstrap confidence interval) for venetoclax apparent clearance, central and peripheral volumes of distribution, intercompartmental clearance, absorption rate constant, and lag time were 16."	( Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Medema, JK; Minocha, M; Othman, AA; Zeng, J, 2018)	0.48
" Among these new drugs, venetoclax, an orally bioavailable BCL2 inhibitor, has shown high efficacy also in relapsed/refractory CLL with TP53 disruption."	( Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. Diop, F; Favini, C; Gaidano, G; Kodipad, AA; Moia, R, 2018)	0.48
" Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2)."	( Venetoclax: Targeting BCL2 in Hematological Cancers. Jebaraj, BMC; Scheffold, A; Stilgenbauer, S, )	0.5
" Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL."	( Venetoclax for the Treatment of Chronic Lymphocytic Leukemia. Eradat, H, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clinical trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax."	( Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Achreja, A; Bajpai, R; Barwick, BG; Boise, LH; Edgar, CL; Gupta, VA; Lonial, S; Matulis, SM; McBrayer, SK; Mittal, A; Nagrath, D; Nooka, AK; Rupji, M; Shanmugam, M; Sharma, A; Siddiqa, AA; Wei, C, 2020)	0.56
" Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway."	( Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Adams, CB; Farhadfar, N; Li, Y; May, WS, 2021)	0.99
" The recent approval of venetoclax, an orally bioavailable BCL-2 inhibitor, resulted in significant responses in treatment naïve acute myeloid leukemia (AML), and off-label use in the relapsed/refractory setting is increasing."	( The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Byrne, M; Chinratanalab, W; Culos, K; Danielson, N; Dholaria, B; Engelhardt, BG; Ferrell, PB; Fogo, K; Gatwood, K; Goodman, S; Jagasia, M; Jayani, R; Kassim, A; Mohan, SR; Rasche, A; Savani, BN; Savona, M; Sengsayadeth, S; Strickland, SA; Wyatt, H, 2020)	0.56
"Venetoclax (VX) used in the treatment of chronic lymphocytic leukemia possesses low oral bioavailability (5."	( Development and Characterization of Venetoclax Nanocrystals for Oral Bioavailability Enhancement. Chinni, S; Kala, SG, 2021)	0.62
"The pig has been increasingly used as a reliable preclinical model for assessing and predicting the in vivo bioavailability of different formulation strategies."	( Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage - case study of Venetoclax. Griffin, BT; Henze, LJ; Holm, R; Koehl, NJ; O'Shea, JP; Vertzoni, M, 2021)	0.62
" However, pulmonary delivery of free venetoclax is hindered by its water insolubility, which results in limited bioavailability and pharmacological effects."	( Venetoclax nanomedicine alleviates acute lung injury via increasing neutrophil apoptosis. Chen, Z; Li, M; Su, R; Tao, Y; Wang, H; Xiao, C, 2021)	0.62
"This work presents an end-to-end approach for assessing the absolute bioavailability of highly hydrophobic, poorly water-soluble compounds that exhibit high nonspecific binding using venetoclax as a model drug."	( A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic. Alaarg, A; Asmus, LR; Bien, J; Elkinton, T; Grieme, T; Liu, Y; Menon, R; Rizzo, D; Salem, AH, 2022)	0.72
"Lipid based formulations (LBF) have shown to overcome food dependent bioavailability for some poorly water-soluble drugs."	( Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax. De Vijlder, T; Griffin, BT; Henze, LJ; Holm, R; Keating, JJ; Koehl, NJ; Kuentz, M; Marx, A, 2022)	0.72
" Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 that shows efficacy in MM not only as a single agent but also in combination therapy, especially for MM patients with translocation t(11;14)."	( Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. Ejiri, M; Hanamura, I; Kanasugi, J; Nakamura, A; Seto, M; Suzuki, S; Takami, A; Ueda, R, 2021)	0.62
" Asian patients had 67% higher mean relative bioavailability than non-Asian patients, however the range of exposures in Asian patients was similar to non-Asian patients."	( Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Brackman, D; Eckert, D; Gopalakrishnan, S; Hayslip, J; Menon, R; Mensing, S; Miles, D; Potluri, J; Salem, AH; Smith, BD; Wei, AH; Zha, J, 2022)	0.72
" Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents."	( Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M, 2022)	0.72
"Venetoclax, a highly selective Bcl-2 inhibitor, is an orally bioavailable drug that has been approved as first-line therapy for chronic lymphocytic leukemia (CLL) in combination with obinutuzumab, as well as monotherapy in the setting of relapsed CLL."	( Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia. Abdeen, M; Asawa, P; Felton, K; Khan, C; Lister, J; Rinchuse, D; Samhouri, Y; Vusqa, UT, 2022)	0.72
"Venetoclax, an orally bioavailable BCL-2 inhibitor, has been regarded as a breakthrough for the treatment of leukemia but has a wide interindividual variability and drug-drug interaction in pharmacokinetics."	( Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients. Fang, X; Gao, P; Guo, N; Leng, B; Liu, X; Wang, X; Zhang, W; Zhang, Y, 2023)	0.91
" Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21)."	( Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Fukuda-Kurahashi, Y; Hoshiko, T; Kamachi, K; Kawasoe, K; Kimura, S; Kurahashi, Y; Ureshino, H; Watanabe, T; Yamamoto, Y; Yoshida-Sakai, N, 2023)	0.91
" Newly identified covariate effects include 48% lower CL/F in subjects with severe hepatic impairment, 61% higher bioavailability in Asian subjects."	( Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials. Deng, R; Gong, JQX; Menon, R; Mensing, S; Salem, AH; Suleiman, AA, 2023)	0.91
" Venetoclax (ABT-199) is an orally bioavailable Bcl-2 (B-cell lymphoma 2) inhibitor that stimulates apoptotic signaling pathways in cancer cells."	( The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells. Karademir, D; Özgür, A, 2023)	1.53
"XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7."	( Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax. Bagal, B; Dutt, A; Gaur, T; Gupta, S; Hasan, SK; Khare, L; Khattry, N; Konopleva, M; Patkar, N; Pg, S; Platzbeckar, U; Poddutoori, R; Ramchandra, M; Rashmi, S; Samajdar, S; Shetty, D; Tembhare, P; Zhang, Q, 2023)	0.91

Excerpt	Relevance	Reference
" On-target tumor lysis syndrome (TLS) has been observed in a subset of patients treated with ABT-199, but changes in initial dosing and stepwise dose escalation have now been implemented to mitigate this risk."	( Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Davids, MS; Ng, SY, 2014)	0.62
" Patients were then given daily 400 mg continuous dosing until disease progression or discontinuation for another reason."	( Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Böttcher, S; Cerri, E; Chyla, B; Coutre, S; Desai, M; Eichhorst, B; Enschede, SH; Gordon, G; Hallek, M; Humerickhouse, R; Jurczak, W; Mobasher, M; Mulligan, SP; Munir, T; Puvvada, SD; Roberts, AW; Schetelig, J; Seymour, JF; Stilgenbauer, S; Verdugo, M; Wendtner, CM; Wierda, WG; Zhu, M, 2016)	0.43
" In summary, venetoclax exhibits a pharmacokinetic profile that is compatible with once-daily dosing with food regardless of fat content."	( Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. Agarwal, SK; Dunbar, M; Enschede, SL; Humerickhouse, RA; Salem, AH; Wong, SL, 2017)	0.46
"0 %) at a venetoclax dosage of 400 mg daily, with minimal increase in ORR at higher doses."	( Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Awni, WM; Eckert, D; Freise, KJ; Humerickhouse, RA; Jones, AK; Mensing, S; Salem, AH; Wong, SL, 2017)	0.46
"The exposure-response analyses indicated that a venetoclax dosage regimen of 400 mg daily results in a high (>80 %) probability of achieving OR in R/R CLL/SLL patients, with minimal probability of increasing neutropenia or infection with higher exposures."	( Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Awni, WM; Eckert, D; Freise, KJ; Humerickhouse, RA; Jones, AK; Mensing, S; Salem, AH; Wong, SL, 2017)	0.46
"Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy."	( Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Awni, WM; Freise, KJ; Humerickhouse, RA; Jones, AK; Menon, RM; Salem, AH; Verdugo, ME, 2017)	0.46
"The objectives of the analysis were to develop and verify a venetoclax physiologically based pharmacokinetic (PBPK) model to predict the effects of cytochrome P450 3A (CYP3A) inhibitors and inducers on the PK of venetoclax and inform dosing recommendations."	( Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Freise, KJ; Salem, AH; Shebley, M, 2017)	0.46
" Logistic regression models were utilized to determine relationships, identify subpopulations with different responses, and optimize the venetoclax dosage that balanced both efficacy and safety."	( Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients. Freise, KJ; Jones, AK; Maciag, PC; Menon, RM; Salem, AH; Verdugo, ME, 2017)	0.46
" In early-phase clinical trials in CLL, venetoclax treatment led to tumor lysis syndrome in some patients with a large tumor burden, but this risk was subsequently mitigated by a revised study design that included lower initial dosing with intrapatient dose ramp up and close tumor lysis syndrome monitoring and prophylaxis."	( Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Crombie, J; Davids, MS, 2017)	0.46
" Optimal dosing of PRIT plus venetoclax cured 100% of mice with no detectable toxicity."	( Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Fisher, DR; Gooley, TA; Gopal, AK; Green, DJ; Hamlin, DK; Hylarides, MD; Kenoyer, AL; Lin, Y; O'Steen, S; Orozco, JJ; Press, OW; Till, BG; Waltman, A; Wilbur, DS, 2017)	0.46
" Patients with rapidly progressing disease received an accelerated dosing schedule (to 400 mg per day by week 3)."	( Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018)	0.48
" The study objective was to determine the effect of different dosage regimens of ritonavir, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax in 20 healthy subjects."	( Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Freise, KJ; Hu, B; Salem, AH, 2018)	0.48
" The multiple-dose evaluation consisted of two cycles, each with once-daily dosing for 7 days followed by a 21-day washout."	( Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Medema, JK; Minocha, M; Othman, AA; Zeng, J, 2018)	0.48
" Serial blood samples for the determination of venetoclax concentrations were collected after dosing in both periods."	( Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Agarwal, SK; Bueno, OF; Menon, RM; Salem, AH; Tong, B, 2018)	0.48
"No venetoclax dosage adjustment is required in subjects with mild or moderate hepatic impairment."	( Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Agarwal, SK; Bueno, OF; Dave, N; Hu, B; Marbury, T; Menon, RM; Miles, D; Salem, AH, 2019)	0.51
" We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact of dosing modifications in routine clinical practice."	( Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Allan, JN; Bailey, N; Barr, PM; Brander, DM; Cheson, BD; Coombs, CC; Dorsey, C; Eyre, TA; Fox, CP; Goy, A; Hill, BT; Jacobs, R; Kabel, C; Kirkwood, AA; Lamanna, N; Lansigan, F; Mato, AR; Morse, H; Muralikrishnan, S; Nabhan, C; Pagel, JM; Pearson, L; Rhodes, J; Roeker, LE; Schuh, A; Schuster, SJ; Shadman, M; Shah, NN; Singavi, AK; Sitlinger, A; Skarbnik, AP; Tuncer, HH; Ujjani, CS; Williams, AM; Winter, AM; Yazdy, M, 2019)	0.51
" The updated model was used to describe venetoclax PKs after repeated dosing in combination with rituximab, and to determine post hoc estimates of PK parameters for exposure-response analysis."	( Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Agarwal, P; Boyer, M; Deng, R; Ding, H; Freise, KJ; Gibiansky, L; Girish, S; Humphrey, K; Kater, AP; Kshirsagar, S; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Salem, AH; Seymour, JF; Wang, J, 2019)	0.51
" The purpose of this analysis is to quantify the relationship between venetoclax exposure and B-lymphocyte levels to inform dosing of venetoclax in healthy subjects."	( Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. Dave, N; Gopalakrishnan, S; Mensing, S; Salem, AH, 2019)	0.51
" The developed modeling framework was also used to evaluate venetoclax effects following cyclic, continuous, or induction/maintenance dosing paradigms as potential dosing alternatives in systemic lupus erythematosus."	( Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. Minocha, M; Nader, A; Othman, AA, 2020)	0.56
" Simulations to evaluate changes in B-lymphocyte and total lymphocyte counts following different venetoclax dosing scenarios were conducted."	( Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. Minocha, M; Nader, A; Othman, AA, 2020)	0.56
" To evaluate target engagement of BH3 mimetics in cells, we measured binding potency of ABT-199, A-1210477 and ABT-737 to Bcl-2 and Mcl-1 proteins by using a dose-response cellular thermal shift assay (CETSA), similar affinity rank-order and selectivity were obtained in comparison with in vitro binding assays."	( Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. Guo, Z; Liu, P; Song, T; Xue, Z; Zhang, M; Zhang, X; Zhang, Z, 2020)	0.99
" These models were then used to assess the magnitude of interaction at therapeutic venetoclax doses and to explore various clinical dosing strategies that maintain venetoclax and digoxin concentrations within their respective therapeutic windows."	( Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Alhadab, AA; Freise, KJ; Salem, AH, 2020)	0.56
" Dosing and safety data were drawn from clinical trials and US package inserts."	( Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Cho, SK; Davids, MS; Johnson, S; Kapustyan, T; Manzoor, BS; Parisé, H; Ravelo, A; Sail, KR; Shapouri, S; Sharmokh, S; Virabhak, S, 2020)	0.56
" Although extensive data exist for adult myeloid malignancies, there are limited preclinical data on the efficacy and/or dosing of venetoclax for pediatric myelodysplastic syndrome (MDS) or AML and thus little information to guide use of this regimen in pediatric patients."	( Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Franklin, AK; Gore, L; Maloney, KW; Treece, AL; Winters, AC, 2020)	0.56
" Using data from 435 patients with relapsed or refractory CLL, an integrated model was developed and validated that accounted for venetoclax dosing and pharmacokinetics, rituximab treatment, absolute lymphocyte count, and blood and bone marrow (BM) MRD data."	( Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Awni, W; Chyla, B; Freise, KJ; Gopalakrishnan, S; Humerickhouse, R; Menon, R; Mensing, S; Miles, D; Salem, AH; Wierda, W, 2021)	0.62
"Our findings suggest low dose combinations of venetoclax and BETi may be more efficacious for patients with AML than either monotherapy, potentially providing a longer, more tolerable dosing regimen."	( BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Arrate, MP; Boyd, K; Childress, M; Fischer, MA; Fuller, L; Gorska, AE; Greenwood, D; Hiebert, SW; Liu, PCC; Ramsey, HE; Rathmell, JC; Savona, MR; Stengel, K; Stubbs, MC; Zhang, S; Zhao, Y, 2021)	0.62
" The clinically verified posaconazole PBPK models were then utilized to predict DDI with a previously published venetoclax PBPK model at clinically relevant dosing scenarios."	( Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach. Bhatnagar, S; Gibbs, JP; Menon, RM; Miles, D; Mukherjee, D; Salem, AH, 2021)	0.62
" Compared with a regimen of oral free VTX, the intravenous regimen in those studies used a VTX dosage that was 15-30 times smaller for an OCI-AML-2 xenograft model and a dosing regimen that was less frequent for an MV4-11 xenograft model."	( A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML). Ando, H; Eshima, K; Ishida, T; Murakami, Y, 2022)	0.72
" Acalabrutinib monotherapy was given orally at 100 mg twice daily for cycle 1, then combined for six cycles with intravenous obinutuzumab (100 mg on cycle 2 day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 and on day 1 of cycles 3-7); and from the beginning of cycle 4, oral venetoclax was dosed daily using an accelerated ramp-up from 20 mg on day 1 to 400 mg by day 22 and continued at this dose thereafter."	( Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Armand, P; Arnason, JE; Brown, JR; Crombie, JL; Davids, MS; Fisher, DC; Jacobson, CA; Kim, AI; LaCasce, AS; Lampson, BL; Lowney, JC; Montegaard, J; Ng, SY; Patterson, V; Pazienza, S; Tyekucheva, S; Wang, Z; Weinstock, M, 2021)	0.62
" Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents."	( A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Abdallah, AO; Arriola, E; Bowles, KM; Bueno, OF; Coppola, S; Gasparetto, C; Mander, G; Mateos, MV; Morris, L; Ross, JA; Wang, J, 2021)	0.62
" We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily)."	( Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME, 2022)	0.72
" Therefore, individualized dosing using therapeutic drug monitoring (TDM) may help to optimize treatment in clinical practice."	( Determination of Venetoclax Concentration in Plasma Using High-Performance Liquid Chromatography. Gando, Y; Kobayashi, M; Kosugi, N; Nomura, Y; Yasu, T, 2023)	0.91
" Additionally, newly developed oral suspension powder formulations to facilitate dosing in pediatrics were evaluated."	( Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Badawi, M; Chen, X; Hoffman, D; Koenigsdorfer, A; Marroum, P; Menon, R; Mensing, S; Palenski, T; Salem, AH; Samineni, D; Schiele, JT; Suleiman, AA, 2022)	0.72
" Venetoclax treatment variables included dosing information, schedule modifications, and drug-drug interactions."	( Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US. Abbas, JA; Bui, CN; Donnellan, W; Flahavan, EM; Flores, B; Gershon, A; Jin, H; Ku, G; Ma, E; Montez, M; Onishi, M; Vachhani, P; Xu, T, 2022)	0.72
" However, the dosage of venetoclax is fixed, irrespective of body surface area (BSA) or weight."	( Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T, 2022)	0.72
" Two-dimensional dose escalation (DE, n = 50) was performed for venetoclax daily with idasanutlin on days 1 to 5 in 28-day cycles, followed by dosing schedule optimization (n = 6) to evaluate reduced venetoclax schedules (21-/14-day dosing)."	( Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Andreeff, M; Assouline, S; Brandwein, JM; Dail, M; Daver, NG; Fenaux, P; Garcia, JS; Green, C; Hong, WJ; Huang, W; Jonas, BA; Kelly, KR; Konopleva, MY; Martinelli, G; Olin, RL; Onishi, M; Ott, MG; Paolini, S; Pigneux, A; Pollyea, DA; Powell, BL; Roboz, GJ; Tafuri, A; Vey, N; Visani, G; Wang, J; Yee, KWL, 2023)	0.91
" Dosage adjustments for drug interactions and safety varied between centers."	( Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A, 2023)	0.91
" Lenalidomide was dosed at 20 mg daily from days 1 to 21 of each 28-day cycle."	( Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Bond, D; Boonstra, P; Carty, SA; Danilov, AV; Herrera, AF; Kaminski, MS; Kandarpa, M; Karimi, YH; Kump, K; Maddocks, K; Mayer, TL; Nachar, V; Nikolovska-Coleska, Z; Phillips, TJ; Popplewell, L; Takiar, R; Wilcox, RA, 2023)	0.91

Role	Description
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
B-cell lymphoma 2 inhibitor	Any inhibitor of B-cell lymphoma 2 protein.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
oxanes	Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
N-sulfonylcarboxamide	A mixed diacylamine resulting from the formal condensation of the nitrogen of a carboxamide with a sulphonic acid.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
pyrrolopyridine
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
N-arylpiperazine
N-alkylpiperazine
C-nitro compound	A nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Small cell lung cancer	0	3

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	22.5226	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	1.5849	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Apoptosis regulator Bcl-2	Homo sapiens (human)	IC50 (µMol)	0.3067	0.0010	0.5763	4.3000	AID1326250; AID1368926; AID1418235; AID1535344; AID1769238; AID1778297; AID1802502; AID1845787
Apoptosis regulator Bcl-2	Homo sapiens (human)	Ki	0.0057	0.0000	0.1901	2.9000	AID1293719; AID1326250; AID1352868; AID1380344; AID1388438; AID1483476; AID1580119; AID1599454; AID1674225; AID1812572; AID1853858; AID1853861; AID1853862; AID1907203
Bcl-2-like protein 1	Homo sapiens (human)	IC50 (µMol)	0.4667	0.0003	1.0482	9.5400	AID1368927; AID1418236; AID1769239; AID1802502
Bcl-2-like protein 1	Homo sapiens (human)	Ki	0.0346	0.0000	0.4581	9.0000	AID1293720; AID1352869; AID1388439; AID1483477; AID1754975; AID1812571; AID1907199
Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)	IC50 (µMol)	1.4009	0.0044	2.9235	10.0000	AID1326249; AID1802502
Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)	Ki	40.4224	0.0010	1.4653	9.5400	AID1326249; AID1352870; AID1483479; AID1754973; AID1907201
Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)	IC50 (µMol)	1.4450	0.0200	2.6609	9.4300	AID1677972; AID1677973; AID1677974; AID1677975
Bcl-2-related protein A1	Homo sapiens (human)	IC50 (µMol)	0.7511	0.0044	1.6514	4.3000	AID1802502
Bcl-2-like protein 2	Homo sapiens (human)	Ki	0.2450	0.0010	1.2590	8.1900	AID1483478; AID1907198
Bcl2-associated agonist of cell death	Homo sapiens (human)	Ki	16.0000	0.0005	0.1589	0.4900	AID1754974
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Apoptosis regulator Bcl-2	Homo sapiens (human)	EC50 (µMol)	0.0030	0.0030	0.1348	0.8500	AID1545359
Apoptosis regulator Bcl-2	Homo sapiens (human)	Kd	0.3540	0.0006	0.9587	4.8000	AID1700823; AID1700824
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
protein polyubiquitination	Apoptosis regulator Bcl-2	Homo sapiens (human)
apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to xenobiotic stimulus	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to toxic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of cell growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to cytokine	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of calcium ion transport	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Apoptosis regulator Bcl-2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Apoptosis regulator Bcl-2	Homo sapiens (human)
ossification	Apoptosis regulator Bcl-2	Homo sapiens (human)
ovarian follicle development	Apoptosis regulator Bcl-2	Homo sapiens (human)
metanephros development	Apoptosis regulator Bcl-2	Homo sapiens (human)
branching involved in ureteric bud morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
behavioral fear response	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
release of cytochrome c from mitochondria	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of cell-matrix adhesion	Apoptosis regulator Bcl-2	Homo sapiens (human)
lymphoid progenitor cell differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell lineage commitment	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of B cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to ischemia	Apoptosis regulator Bcl-2	Homo sapiens (human)
renal system process	Apoptosis regulator Bcl-2	Homo sapiens (human)
melanin metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of nitrogen utilization	Apoptosis regulator Bcl-2	Homo sapiens (human)
autophagy	Apoptosis regulator Bcl-2	Homo sapiens (human)
humoral immune response	Apoptosis regulator Bcl-2	Homo sapiens (human)
DNA damage response	Apoptosis regulator Bcl-2	Homo sapiens (human)
actin filament organization	Apoptosis regulator Bcl-2	Homo sapiens (human)
axonogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
female pregnancy	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of cell population proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
male gonad development	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to radiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to xenobiotic stimulus	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to toxic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
post-embryonic development	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to iron ion	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to UV-B	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to gamma radiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of gene expression	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of autophagy	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of calcium ion transport into cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of glycoprotein biosynthetic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
mesenchymal cell development	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of neuron maturation	Apoptosis regulator Bcl-2	Homo sapiens (human)
smooth muscle cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
cochlear nucleus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
gland morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of transmembrane transporter activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of ossification	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cell growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
melanocyte differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cell migration	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of B cell proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
hair follicle morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
axon regeneration	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of protein stability	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
glomerulus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of cellular pH reduction	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of protein localization	Apoptosis regulator Bcl-2	Homo sapiens (human)
myeloid cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of myeloid cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell differentiation in thymus	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Apoptosis regulator Bcl-2	Homo sapiens (human)
osteoblast proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of osteoblast proliferation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to nicotine	Apoptosis regulator Bcl-2	Homo sapiens (human)
organ growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of multicellular organism growth	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to glucose starvation	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to hydrogen peroxide	Apoptosis regulator Bcl-2	Homo sapiens (human)
neuron maturation	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell homeostasis	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitment	Apoptosis regulator Bcl-2	Homo sapiens (human)
ear development	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of viral genome replication	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of melanocyte differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
retinal cell programmed cell death	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of retinal cell programmed cell death	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Apoptosis regulator Bcl-2	Homo sapiens (human)
focal adhesion assembly	Apoptosis regulator Bcl-2	Homo sapiens (human)
spleen development	Apoptosis regulator Bcl-2	Homo sapiens (human)
thymus development	Apoptosis regulator Bcl-2	Homo sapiens (human)
digestive tract morphogenesis	Apoptosis regulator Bcl-2	Homo sapiens (human)
oocyte development	Apoptosis regulator Bcl-2	Homo sapiens (human)
skeletal muscle fiber development	Apoptosis regulator Bcl-2	Homo sapiens (human)
positive regulation of skeletal muscle fiber development	Apoptosis regulator Bcl-2	Homo sapiens (human)
pigment granule organization	Apoptosis regulator Bcl-2	Homo sapiens (human)
stem cell development	Apoptosis regulator Bcl-2	Homo sapiens (human)
homeostasis of number of cells within a tissue	Apoptosis regulator Bcl-2	Homo sapiens (human)
B cell receptor signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to glucocorticoid	Apoptosis regulator Bcl-2	Homo sapiens (human)
neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
defense response to virus	Apoptosis regulator Bcl-2	Homo sapiens (human)
establishment of localization in cell	Apoptosis regulator Bcl-2	Homo sapiens (human)
regulation of mitochondrial membrane potential	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Apoptosis regulator Bcl-2	Homo sapiens (human)
hematopoietic stem cell differentiation	Apoptosis regulator Bcl-2	Homo sapiens (human)
calcium ion transport into cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
T cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of T cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to organic substance	Apoptosis regulator Bcl-2	Homo sapiens (human)
cellular response to hypoxia	Apoptosis regulator Bcl-2	Homo sapiens (human)
reactive oxygen species metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
dendritic cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
motor neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
cell-cell adhesion	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Apoptosis regulator Bcl-2	Homo sapiens (human)
epithelial cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of epithelial cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of dendritic cell apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of motor neuron apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of anoikis	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Apoptosis regulator Bcl-2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Apoptosis regulator Bcl-2	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Apoptosis regulator Bcl-2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Apoptosis regulator Bcl-2	Homo sapiens (human)
response to cytokine	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	Bcl-2-like protein 1	Homo sapiens (human)
ovarian follicle development	Bcl-2-like protein 1	Homo sapiens (human)
in utero embryonic development	Bcl-2-like protein 1	Homo sapiens (human)
release of cytochrome c from mitochondria	Bcl-2-like protein 1	Homo sapiens (human)
endocytosis	Bcl-2-like protein 1	Homo sapiens (human)
germ cell development	Bcl-2-like protein 1	Homo sapiens (human)
spermatogenesis	Bcl-2-like protein 1	Homo sapiens (human)
male gonad development	Bcl-2-like protein 1	Homo sapiens (human)
apoptotic mitochondrial changes	Bcl-2-like protein 1	Homo sapiens (human)
fertilization	Bcl-2-like protein 1	Homo sapiens (human)
regulation of cytokinesis	Bcl-2-like protein 1	Homo sapiens (human)
positive regulation of mononuclear cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
ectopic germ cell programmed cell death	Bcl-2-like protein 1	Homo sapiens (human)
regulation of growth	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of neuron apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
dendritic cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
response to cycloheximide	Bcl-2-like protein 1	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Bcl-2-like protein 1	Homo sapiens (human)
epithelial cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of developmental process	Bcl-2-like protein 1	Homo sapiens (human)
neuron apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
defense response to virus	Bcl-2-like protein 1	Homo sapiens (human)
regulation of mitochondrial membrane potential	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to amino acid stimulus	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to alkaloid	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to gamma radiation	Bcl-2-like protein 1	Homo sapiens (human)
apoptotic process in bone marrow cell	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Bcl-2-like protein 1	Homo sapiens (human)
dendritic cell apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
hepatocyte apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of execution phase of apoptosis	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of protein localization to plasma membrane	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of reproductive process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of dendritic cell apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Bcl-2-like protein 1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-like protein 1	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-like protein 1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
DNA damage response	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
response to cytokine	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cell fate determination	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of autophagy	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cellular homeostasis	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
positive regulation of apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein transmembrane transport	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of anoikis	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial fusion	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
release of cytochrome c from mitochondria	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
muscle contraction	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
pattern specification process	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
cell population proliferation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
negative regulation of cell population proliferation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
regulation of protein stability	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
limb morphogenesis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
positive regulation of proteolysis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
roof of mouth development	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
face morphogenesis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
regulation of protein depolymerization	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
peptidyl-aspartic acid hydroxylation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-related protein A1	Homo sapiens (human)
transmembrane transport	Bcl-2-related protein A1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-related protein A1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl-2-related protein A1	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-related protein A1	Homo sapiens (human)
release of cytochrome c from mitochondria	Bcl-2-related protein A1	Homo sapiens (human)
mitochondrial fusion	Bcl-2-related protein A1	Homo sapiens (human)
response to ischemia	Bcl-2-like protein 2	Homo sapiens (human)
spermatogenesis	Bcl-2-like protein 2	Homo sapiens (human)
negative regulation of mitochondrial membrane permeability	Bcl-2-like protein 2	Homo sapiens (human)
regulation of apoptotic process	Bcl-2-like protein 2	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-like protein 2	Homo sapiens (human)
Sertoli cell proliferation	Bcl-2-like protein 2	Homo sapiens (human)
cellular response to estradiol stimulus	Bcl-2-like protein 2	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Bcl-2-like protein 2	Homo sapiens (human)
cellular response to amyloid-beta	Bcl-2-like protein 2	Homo sapiens (human)
cellular response to glycine	Bcl-2-like protein 2	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-like protein 2	Homo sapiens (human)
release of cytochrome c from mitochondria	Bcl-2-like protein 2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-like protein 2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl-2-like protein 2	Homo sapiens (human)
glucose catabolic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
apoptotic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Bcl2-associated agonist of cell death	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of autophagy	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of mitochondrial membrane potential	Bcl2-associated agonist of cell death	Homo sapiens (human)
cytokine-mediated signaling pathway	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of insulin secretion	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of glucokinase activity	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulus	Bcl2-associated agonist of cell death	Homo sapiens (human)
glucose homeostasis	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of apoptotic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
type B pancreatic cell proliferation	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of B cell differentiation	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of T cell differentiation	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of proteolysis	Bcl2-associated agonist of cell death	Homo sapiens (human)
ADP metabolic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
ATP metabolic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Bcl2-associated agonist of cell death	Homo sapiens (human)
pore complex assembly	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Bcl2-associated agonist of cell death	Homo sapiens (human)
cellular response to mechanical stimulus	Bcl2-associated agonist of cell death	Homo sapiens (human)
cellular response to nicotine	Bcl2-associated agonist of cell death	Homo sapiens (human)
cellular response to lipid	Bcl2-associated agonist of cell death	Homo sapiens (human)
cellular response to hypoxia	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Bcl2-associated agonist of cell death	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Bcl2-associated agonist of cell death	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Bcl2-associated agonist of cell death	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Bcl2-associated agonist of cell death	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Bcl2-associated agonist of cell death	Homo sapiens (human)
positive regulation of type B pancreatic cell development	Bcl2-associated agonist of cell death	Homo sapiens (human)
release of cytochrome c from mitochondria	Bcl2-associated agonist of cell death	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protease binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
channel activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
channel inhibitor activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
ubiquitin protein ligase binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
identical protein binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
sequence-specific DNA binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein heterodimerization activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
BH3 domain binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein phosphatase 2A binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
molecular adaptor activity	Apoptosis regulator Bcl-2	Homo sapiens (human)
DNA-binding transcription factor binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
BH domain binding	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein binding	Bcl-2-like protein 1	Homo sapiens (human)
protein kinase binding	Bcl-2-like protein 1	Homo sapiens (human)
identical protein binding	Bcl-2-like protein 1	Homo sapiens (human)
BH3 domain binding	Bcl-2-like protein 1	Homo sapiens (human)
BH domain binding	Bcl-2-like protein 1	Homo sapiens (human)
protein binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein transmembrane transporter activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
protein heterodimerization activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
BH3 domain binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
channel activity	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
BH domain binding	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
structural molecule activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
calcium ion binding	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
protein binding	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
structural constituent of muscle	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
electron transfer activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
protein binding	Bcl-2-related protein A1	Homo sapiens (human)
channel activity	Bcl-2-related protein A1	Homo sapiens (human)
BH domain binding	Bcl-2-related protein A1	Homo sapiens (human)
protein binding	Bcl-2-like protein 2	Homo sapiens (human)
identical protein binding	Bcl-2-like protein 2	Homo sapiens (human)
protein-containing complex binding	Bcl-2-like protein 2	Homo sapiens (human)
disordered domain specific binding	Bcl-2-like protein 2	Homo sapiens (human)
BH domain binding	Bcl-2-like protein 2	Homo sapiens (human)
protein binding	Bcl2-associated agonist of cell death	Homo sapiens (human)
phospholipid binding	Bcl2-associated agonist of cell death	Homo sapiens (human)
lipid binding	Bcl2-associated agonist of cell death	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Bcl2-associated agonist of cell death	Homo sapiens (human)
protein kinase binding	Bcl2-associated agonist of cell death	Homo sapiens (human)
protein phosphatase binding	Bcl2-associated agonist of cell death	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrial outer membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
nucleus	Apoptosis regulator Bcl-2	Homo sapiens (human)
cytoplasm	Apoptosis regulator Bcl-2	Homo sapiens (human)
mitochondrion	Apoptosis regulator Bcl-2	Homo sapiens (human)
mitochondrial outer membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
endoplasmic reticulum	Apoptosis regulator Bcl-2	Homo sapiens (human)
cytosol	Apoptosis regulator Bcl-2	Homo sapiens (human)
membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
nuclear membrane	Apoptosis regulator Bcl-2	Homo sapiens (human)
myelin sheath	Apoptosis regulator Bcl-2	Homo sapiens (human)
BAD-BCL-2 complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
protein-containing complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
pore complex	Apoptosis regulator Bcl-2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytoplasm	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrion	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial inner membrane	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial matrix	Bcl-2-like protein 1	Homo sapiens (human)
endoplasmic reticulum	Bcl-2-like protein 1	Homo sapiens (human)
centrosome	Bcl-2-like protein 1	Homo sapiens (human)
cytosol	Bcl-2-like protein 1	Homo sapiens (human)
synaptic vesicle membrane	Bcl-2-like protein 1	Homo sapiens (human)
nuclear membrane	Bcl-2-like protein 1	Homo sapiens (human)
Bcl-2 family protein complex	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-like protein 1	Homo sapiens (human)
nucleus	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
nucleoplasm	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cytoplasm	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrion	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial outer membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
cytosol	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
Bcl-2 family protein complex	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
mitochondrial outer membrane	Induced myeloid leukemia cell differentiation protein Mcl-1	Homo sapiens (human)
endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
endoplasmic reticulum membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
plasma membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
cortical endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
sarcoplasmic reticulum membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
cytoplasm	Bcl-2-related protein A1	Homo sapiens (human)
cytosol	Bcl-2-related protein A1	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-related protein A1	Homo sapiens (human)
cytosol	Bcl-2-like protein 2	Homo sapiens (human)
Bcl-2 family protein complex	Bcl-2-like protein 2	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-like protein 2	Homo sapiens (human)
mitochondrion	Bcl2-associated agonist of cell death	Homo sapiens (human)
mitochondrial outer membrane	Bcl2-associated agonist of cell death	Homo sapiens (human)
cytosol	Bcl2-associated agonist of cell death	Homo sapiens (human)
BAD-BCL-2 complex	Bcl2-associated agonist of cell death	Homo sapiens (human)
cytosol	Bcl2-associated agonist of cell death	Homo sapiens (human)
mitochondrion	Bcl2-associated agonist of cell death	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (213)

Assay ID	Title	Year	Journal	Article
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347157	Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156	DAPI mCherry counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1802502	DELFIA from Article 10.1021/acschembio.6b00962: \\hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.\\	2017	ACS chemical biology, 02-17, Volume: 12, Issue:2	hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.
AID1769252	Tmax in mouse at 10 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1769245	Metabolic stability in human liver microsomes assessed as parent compound remaining incubated for 60 mins in presence of NADPH	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1326250	Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1769248	AUC (0 to t) in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1853864	Binding affinity to recombinant Bcl-2 V113G mutant (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1668015	Induction of apoptosis in human RS4:11 cells assessed as late apoptotic cells at 0.5 uM after 48 hrs by Annexin-V and 7-AAD staining based flow cytometric analysis (Rvb = 2.71%)	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1353864	Cytotoxicity against human BL2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID1769240	Antiproliferative activity against human RS4-11 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1668008	Antiproliferative activity against human HL60 cells assessed as growth inhibition at 1 uM after 48 hrs by CCK-8 assay relative to control	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1677973	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1677975	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1845326	Antitumor activity against human MOLM-13 cells inoculated orthotopic acute myeloid leukemia mouse model assessed as tumor regression at 50 mg/kg, po daily in presence of AMG 397 and measured after 1 week	2021	Bioorganic & medicinal chemistry letters, 01-15, Volume: 32	Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
AID1483479	Binding affinity to Mcl-1 (unknown origin) by TR-FRET assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1812600	Binding affinity to full length human MCL1 expressed in Escherichia coli BL21 (DE3) at up to 100 uM preincubated for 30 mins followed by 5-FAM-QEDIIIINIARHLAQVGDSMD-RSIPPG tracer addition and measured after 20 mins by fluorescence polarization assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1754974	Binding affinity to Bcl-2 (unknown origin) by fluorescence polarization competition assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID1326254	Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1388439	Inhibition of Bcl-xL (unknown origin)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1326259	Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1700825	Binding affinity to human full-length N-terminal His6-tagged Bcl2 R106A/R109A mutant expressed in Escherichia coli S12 extract by isothermal titration calorimetry
AID1677972	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1293719	Binding affinity to Bcl-2 (unknown origin) by FRET assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
AID1353865	Cytotoxicity against human Remb1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID1769251	MRT (0 to t) in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1812574	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1326249	Inhibition of FAM-Bid binding to human MCL1 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1700836	Induction of apoptosis in human MCF7 cells measured after 48 hrs by FITC-Annexin V/PS staining based
AID1769249	AUC (0 to infinity) in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1352869	Inhibition of Bcl-xL (unknown origin) by TR-FRET assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID1812590	Induction of apoptosis in human RS4-11 cells assessed as increase in cleaved caspase 9 expression incubated for 48 hrs by western blot analysis	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1769247	Cmax in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1700847	Induction of BCl-2 dephosphorylation in human HL-60 cells at 1 to 5 uM measured after 24 hrs by coimmunoprecipitation method
AID1769239	Displacement of Bak derived peptide from Bcl-xL (unknown origin) measured after 15 mins by microplate reader assay	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1380343	Solubility of the compound in FaSSIF	2018	Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
AID1853861	Binding affinity to recombinant Bcl-2 D103V mutant (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1769242	Toxicity in C57BL/6 mouse plasma assessed as effect on platelet count at 300 mg/kg, ig for 4 hrs	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1668016	Induction of apoptosis in human RS4:11 cells assessed as necrotic cells at 0.5 uM after 48 hrs by Annexin-V and 7-AAD staining based flow cytometric analysis (Rvb = 0.67%)	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1907223	Induction of apoptosis in human U-937 cells assessed as increase in cytochrome c level incubated for 3 hrs by immunoblotting analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1769257	MRT (0 to t) in mouse at 10 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1700837	Resistance ratio of EC50 for induction of apoptosis in human HL-60 cells to EC50 for Induction of apoptosis in human KG-1 cells
AID1326257	Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1812583	Induction of apoptosis in human RS4-11 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V/7-AAD and MitoSense Red staining based flow cytometry analysis relative to control (Rvb = 3.75 %)	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1778296	Inhibition of FAM-Bim peptide binding to human Hsp70 NBD (1 to 383) measured after 30 mins by fluorescence polarization assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction.
AID1700840	Resistance ratio of EC50 for induction of apoptosis in human OCI-AML-3 cells to EC50 for Induction of apoptosis in human MCF7 cells
AID1326268	Cytotoxicity against human NCI60 cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1418236	Inhibition of FAM-labelled Bax binding to Bcl-xL (unknown origin) after 30 mins by fluorescence polarization assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.
AID1812572	Binding affinity to full length human Bcl-2 expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant preincubated for 30 mins followed by 5-FAM-QEDIIIINIARHLAQVGDSMD-RSIPPG tracer addition and measured after 20 mins by fluorescence polariz	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1769241	Induction of caspase 3 activity in dog platelets assessed as cleavage of Ac-DEVD-Pna at 0.5 to 2.5 uM using Ac-DEVD-pNA as substrate incubated for 90 mins	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1545359	Inhibition of BCL-2 (unknown origin) by fluorescence polarization assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1853863	Binding affinity to recombinant Bcl-2 D129L mutant (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1769254	AUC (0 to t) in mouse at 10 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1545374	Toxicity in mouse xenografted with human haematological tumor at 12.5 mg/kg, po	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1896469	Antitumor activity against human B-lymphocytes harboring Myd88-L265P and CD79B mutant from LY2298 tumor xenografted NOD/SCID mouse model assessed as tumor growth inhibition at 40 mg/kg,po QD measured after 6 hrs	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1418239	Antiproliferative activity against human Toledo cells after 72 hrs by MTS assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.
AID1580119	Inhibition of wild-type BCL-2 (unknown origin) expressed in Escherichia coli BL21 cells using biotinylated BIMBH3 or BAXBH3 peptide by surface plasmon resonance assay	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Hot-Spots of Mcl-1 Protein.
AID1812585	Induction of apoptosis in human RS4-11 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin V/7-AAD and MitoSense Red staining based flow cytometry analysis relative to control (Rvb = 1.11 %)	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1754973	Binding affinity to Mc1-1 (unknown origin) by fluorescence polarization competition assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID1845787	Inhibition of BCL-2 (unknown origin)	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3	A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1700848	Induction of BCl-2 dephosphorylation in human HL-60 cells assessed as increase in Bax expression at 1 to 5 uM measured after 24 hrs by coimmunoprecipitation method
AID1677974	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1326258	Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1769238	Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1769250	Half life in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1388441	Antiproliferative activity against human MOLT4 cells in presence of 10% human serum	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1587689	Antitumor activity against human Maver1 cells xenografted in NSG mouse assessed as inhibition of tumor growth at 20 mg/kg measured on day 13 by caliper method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
AID1380344	Inhibition of Bcl2 (unknown origin)	2018	Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
AID1907263	Induction of apoptosis in human U-937 cells assessed as effect on caspase-3 expression at 50 to 1250 nM measured after 24 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1326261	Cytotoxicity against human breast cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1896473	Toxicity in NOD/SCID mouse xenografted with human LY2298 tumor harboring Myd88-L265P and CD79B mutant assessed as body weight change at 40 mg/kg,po QD measured after 6 hrs	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1700839	Resistance ratio of EC50 for induction of apoptosis in human HL-60 cells to EC50 for Induction of apoptosis in human MCF7 cells
AID1674225	Inhibition of BCL2 (unknown origin) by TR-FRET assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Fragment Linking Strategies for Structure-Based Drug Design.
AID1812584	Induction of apoptosis in human RS4-11 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin V/7-AAD and MitoSense Red staining based flow cytometry analysis relative to control (Rvb = 0.99 %)	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1778297	Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction.
AID1769255	AUC (0 to infinity) in mouse at 10 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1535345	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1812578	Cytotoxicity against HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1483476	Binding affinity to Bcl-2 (unknown origin) by TR-FRET assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1668009	Cytotoxicity against HEK293T cells assessed as growth inhibition at 1 uM after 48 hrs by CCK8 assay relative to control	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1668007	Antiproliferative activity against human RS4:11 cells assessed as growth inhibition at 1 uM after 48 hrs by CCK-8 assay relative to control	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1896471	Antitumor activity against human B-lymphocytes harboring Myd88-L265P and CD79B mutant from LY2298 tumor xenografted NOD/SCID mouse model assessed as tumor growth inhibition at 40 mg/kg,po QD measured after 6 hrs in presence of N-((1R,2S)-2-Acrylamidocyclo	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1907262	Induction of apoptosis in human U-937 cells assessed as effect on PARP expression level at 50 to 1250 nM measured after 24 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1353866	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID1907201	Displacement of fluorescent-labeled BID-BH3 peptide from His-tagged human MCL-1 expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant by fluorescence polarization-based competitive binding assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1853858	Binding affinity to recombinant wild-type Bcl-2 (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1368928	Selectivity factor, ratio of IC50 for Bad-derived peptide from Bcl-XL (unknown origin) to IC50 for displacement of Bax-derived peptide from Bcl-2 (unknown origin)	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors.
AID1418237	Selectivity factor, ratio of IC50 for Bcl-xL (unknown origin) to Bcl2 (unknown origin)	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.
AID1326260	Cytotoxicity against human prostate cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1700824	Binding affinity to human full-length N-terminal His6-tagged prephosphorylated Bcl2 (2 to 206 residues) expressed in Escherichia coli S12 extract by isothermal titration calorimetry
AID1700833	Induction of apoptosis in human HL-60 cells measured after 48 hrs by FITC-Annexin V/PS staining based
AID1769246	Tmax in rat at 5 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1380342	Solubility of the compound in pH 7.4 solution	2018	Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
AID1352864	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID1754975	Binding affinity to Bc1-xL (unknown origin) by fluorescence polarization competition assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID1368927	Displacement of Bad-derived peptide from Bcl-XL (unknown origin) by fluorescence polarization assay	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors.
AID1535346	Growth inhibition of human U266 cells after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1907198	Displacement of fluorescent-labeled BID-BH3 peptide from human BCL-W expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant by fluorescence polarization-based competitive binding assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1882263	Anticancer activity in human multiple myeloma cells	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1812571	Binding affinity to full length human Bcl-xl expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant preincubated for 30 mins followed by 5-FAM-QEDIIIINIARHLAQVGDSMD-RSIPPG tracer addition and measured after 20 mins by fluorescence polari	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1388440	Antiproliferative activity against human RS4:11 cells in presence of 10% human serum	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1599454	Inhibition of Bcl2 (unknown origin)	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	The chemical biology of apoptosis: Revisited after 17 years.
AID1352868	Inhibition of Bcl-2 (unknown origin) by TR-FRET assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID1769244	Metabolic stability in rat liver microsomes assessed as parent compound remaining incubated for 60 mins in presence of NADPH	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1896475	Toxicity in NOD/SCID mouse xenografted with human LY2298 tumor harboring Myd88-L265P and CD79B mutant assessed as body weight change at 40 mg/kg,po QD measured after 6 hrs in presence of N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(S)-(6-isobutyl-4-methylpyridi	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1700850	Induction of BCl-2 dephosphorylation in human OCI-AML-3 cells assessed as increase in Bax expression at 1 to 5 uM measured after 24 hrs by coimmunoprecipitation method
AID1812591	Induction of apoptosis in human RS4-11 cells assessed as increase in cleaved PARP expression incubated for 48 hrs by western blot analysis	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1700849	Induction of BCl-2 dephosphorylation in human OCI-AML-3 cells at 1 to 5 uM measured after 24 hrs by coimmunoprecipitation method
AID1907203	Displacement of fluorescent-labeled BID-BH3 peptide from human BCL-2 expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant by fluorescence polarization-based competitive binding assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1418238	Antiproliferative activity against human RS4:11 cells after 72 hrs by MTS assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.
AID1677971	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) at 20uM using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1700838	Resistance ratio of EC50 for induction of apoptosis in human OCI-AML-3 cells to EC50 for Induction of apoptosis in human KG-1 cells
AID1700834	Induction of apoptosis in human OCI-AML-3 cells measured after 48 hrs by FITC-Annexin V/PS staining based
AID1812577	Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1700835	Induction of apoptosis in human KG-1 cells measured after 48 hrs by FITC-Annexin V/PS staining based
AID1368926	Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors.
AID1352870	Inhibition of Mcl-1 (unknown origin) by TR-FRET assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID1483477	Binding affinity to Bcl-xL (unknown origin) by TR-FRET assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1483478	Binding affinity to Bcl-w (unknown origin) by TR-FRET assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1326253	Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1812582	Induction of apoptosis in human RS4-11 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin V/7-AAD and MitoSense Red staining based flow cytometry analysis relative to control (Rvb = 94.15 %)	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1293720	Binding affinity to Bcl-XL (unknown origin) by FRET assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
AID1812576	Induction of apoptosis in human RS4-11 cells assessed as increase in cleaved caspase 3 expression incubated for 48 hrs by western blot analysis	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1388438	Inhibition of Bcl2 (unknown origin)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1353867	Cytotoxicity against human NCI-H929 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID1668014	Induction of apoptosis in human RS4:11 cells assessed as early apoptotic cells at 0.5 uM after 48 hrs by Annexin-V and 7-AAD staining based flow cytometric analysis (Rvb = 2.56%)	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1853862	Binding affinity to recombinant Bcl-2 D103E mutant (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1418235	Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.
AID1769243	Metabolic stability in mouse liver microsomes assessed as parent compound remaining incubated for 60 mins in presence of NADPH	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1769253	Cmax in mouse at 10 mg/kg, ig administered as single dose v measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1853859	Binding affinity to recombinant Bcl-2 G101V mutant (unknown origin) using peptide probe incubated for 2 hrs by fluorescence based assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
AID1668013	Induction of apoptosis in human RS4:11 cells assessed as viable cells at 0.5 uM after 48 hrs by Annexin-V and 7-AAD staining based flow cytometric analysis (Rvb = 94.06%)	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.
AID1700826	Binding affinity to human full-length N-terminal His6-tagged prephosphorylated Bcl2 R106A/R109A mutant expressed in Escherichia coli S12 extract by isothermal titration calorimetry
AID1907199	Displacement of fluorescent-labeled BID-BH3 peptide from human BCL-xL expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant by fluorescence polarization-based competitive binding assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
AID1326256	Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1751312	Cytotoxicity against human K562 cells assessed as cell survival measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Dual Bcl-X
AID1700823	Binding affinity to human full-length N-terminal His6-tagged Bcl2 (2 to 206 residues) expressed in Escherichia coli S12 extract by isothermal titration calorimetry
AID1535344	Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1812575	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Structure-Based Optimization of 3-Phenyl-
AID1326255	Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1769256	Half life in mouse at 10 mg/kg, ig administered as single dose measured upto 24 hrs by LC-MS/MS analysis	2021	Bioorganic & medicinal chemistry, 10-01, Volume: 47	Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346193	Human BCL2, apoptosis regulator (B-cell lymphoma 2 (Bcl-2) protein family)	2013	Nature medicine, Feb, Volume: 19, Issue:2	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
AID1346232	Human Bcl-2-like 1 (B-cell lymphoma 2 (Bcl-2) protein family)	2013	Nature medicine, Feb, Volume: 19, Issue:2	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
AID1346192	Human Bcl-2-like 2 (B-cell lymphoma 2 (Bcl-2) protein family)	2013	Nature medicine, Feb, Volume: 19, Issue:2	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
AID1346150	Human MCL1, BCL2 family apoptosis regulator (B-cell lymphoma 2 (Bcl-2) protein family)	2013	Nature medicine, Feb, Volume: 19, Issue:2	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
AID1347170	Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171	Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172	Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	469 (31.88)	24.3611
2020's	1002 (68.12)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	150 (10.11%)	5.53%
Reviews	230 (15.51%)	6.00%
Case Studies	133 (8.97%)	4.05%
Observational	4 (0.27%)	0.25%
Other	966 (65.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
alpha-hydroxyglutarate 2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.. 2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.	2.11	1	0	2-hydroxydicarboxylic acid; dicarboxylic fatty acid	metabolite; mouse metabolite
adenine [no description available]	18.14	123	22	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	13.73	11	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
hydroquinone [no description available]	7.25	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	4.1	4	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
pteridines [no description available]	2.13	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; pteridines
pyrogallol benzenetriol : A triol in which three hydroxy groups are substituted onto a benzene ring.	3.31	1	0	benzenetriol; phenolic donor	plant metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.69	2	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	3.8	1	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
b 844-39 [no description available]	2.15	1	0	diarylmethane
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.89	3	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.41	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
hoe 33342 BXI-72: structure in first source	3.31	1	0	bibenzimidazole; N-methylpiperazine	fluorochrome
jtv519 [no description available]	2.89	3	0
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	3.35	1	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.35	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.89	3	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
dan 2163 [no description available]	2.89	3	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.89	3	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.89	3	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
benzamidine benzamidine: RN given refers to parent cpd. benzamidine : A carboxamidine that is benzene carrying an amidino group.	3.35	1	0	benzenes; carboxamidine	serine protease inhibitor
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.89	3	0	1-benzofurans; aromatic ketone	uricosuric drug
berberine [no description available]	2.25	1	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	2.89	3	0
bufexamac Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.	2.89	3	0	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
busulfan [no description available]	6.78	5	2	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
cadralazine cadralazine: structure given in first source	2.89	3	0	organic molecular entity
carvedilol [no description available]	2.63	2	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	2.63	2	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	9.08	13	3	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	2.89	3	0	diarylmethane
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.89	3	0	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
cyclosporine cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.	2.59	2	0
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	3.35	1	0	tertiary amine
embelin embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.	2.31	1	0	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.89	3	0	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.15	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
go 6976 [no description available]	2.89	3	0	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	5.84	8	0
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.89	3	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
homochlorocyclizine homochlorocyclizine: RN given refers to parent cpd	2.89	3	0	diarylmethane
hydroxyurea [no description available]	2.31	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.89	3	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ifenprodil ifenprodil: NMDA receptor antagonist	2.89	3	0	piperidines
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone ZM39923: structure in first source	2.89	3	0	naphthalenes
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.89	3	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	4.45	1	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.89	3	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
letrozole [no description available]	4.43	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.72	2	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.89	3	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mephenesin Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.	2.89	3	0	aromatic ether; glycerol ether
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.63	2	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.31	1	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.31	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.89	3	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
oxibendazole oxibendazole: structure	2.89	3	0	benzimidazoles; carbamate ester
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.35	1	0	aminobenzoic acid; phenols	antitubercular agent
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source	2.89	3	0
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.89	3	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.89	3	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
4-aminobenzoic acid para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.	3.27	5	0	aminobenzoate; aromatic amino-acid anion	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.89	3	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.59	2	0	indoles
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	2.89	3	0	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
ropinirole [no description available]	2.89	3	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.28	5	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	7.82	5	1	phthalimides; piperidones
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.59	2	0	stilbenoid
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.15	1	0	aromatic ketone
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.25	1	0
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.	2.89	3	0	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zotepine zotepine: structure	2.89	3	0	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	9.71	11	4	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
biguanides Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.	2.13	1	0	guanidines
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	4.48	4	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.17	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.31	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.31	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.89	3	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.31	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	2.89	3	0	aromatic ketone
cytarabine [no description available]	17.31	93	17	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.25	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
cyclizine Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.	2.21	1	0	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.21	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.13	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.69	2	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
4-phenylphenol 4-phenylphenol: RN given refers to cpd without isomeric designation. biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.	4.24	2	0	hydroxybiphenyls
quinaldic acid [no description available]	3.35	1	0	quinolinemonocarboxylic acid	human metabolite; Saccharomyces cerevisiae metabolite
trehalose alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.	2.89	3	0	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	4.29	2	0	quinuclidines; saturated organic heterobicyclic parent
triclocarban triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.	2.89	3	0	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	6.97	8	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	7.09	20	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
methylergonovine Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)	2.31	1	0	ergoline alkaloid
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.13	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
4-tert-octylphenol 4-tert-octylphenol: structure given in first source	2.89	3	0	alkylbenzene
hexanoic acid hexanoic acid : A C6, straight-chain saturated fatty acid.	3.35	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	human metabolite; plant metabolite
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.31	1	0	purine nucleoside
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.63	2	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.59	2	0	indazole
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	4.33	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	5.61	4	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.61	2	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.13	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	13.04	28	6	diazine; pyrazines	Daphnia magna metabolite
hydrazine diamine : Any polyamine that contains two amino groups.	4.21	4	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
ethamivan ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.	2.89	3	0	methoxybenzenes; phenols
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	18.38	171	20	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.53	2	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
methysergide Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.	2.89	3	0	ergoline alkaloid
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	2.15	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.6	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.89	3	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.25	1	0	pyridinedicarboxylic acid
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	7.26	10	0
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.15	1	0	thiazolidine
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.89	3	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
etonitazene etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals	2.89	3	0
deoxycytidine [no description available]	2.9	3	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	5.04	5	0
clothiapine clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine	2.89	3	0	dibenzothiazepine
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.89	3	0	aromatic ketone
7-hydroxychlorpromazine 7-hydroxychlorpromazine: RN given refers to parent cpd	2.89	3	0	phenothiazines
acadesine [no description available]	7.53	2	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.	3.51	1	0	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
cladribine [no description available]	7.72	5	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	12.68	20	9	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
actinium Actinium: A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, and atomic number 89. Its principal isotope is 227 and it decays primarily by beta-emission.	3.23	1	0	actinoid atom; f-block element atom; scandium group element atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.09	4	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
aluminum sulfate aluminium sulfate (anhydrous) : An aluminium sulfate that contains no water of crystallisation.	2.15	1	0	aluminium sulfate
thenalidine thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure	2.89	3	0	dialkylarylamine; tertiary amino compound
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	15.84	22	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.89	3	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.21	1	0	benzenes; phenyl acetates
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	2.89	3	0	chlorphenamine
dv 1006 [no description available]	2.89	3	0
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	7.61	2	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	5.5	4	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
climbazole 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.	2.89	3	0	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
triadimenol triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.	2.89	3	0	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	9.63	10	4	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	2.89	3	0	isoquinolines
bisantrene bisantrene: RN given refers to parent cpd; synonyms CL 216942 & NSC 337766 refers to di-HCl. bisantrene : A hydrazone resulting from the formal condensation of both of the aldehyde groups of anthracene-9,10-dicarbaldehyde with 2-hydrazinyl-4,5-dihydro-1H-imidazole.	2.41	1	0	anthracenes; hydrazone; imidazolidines	antineoplastic agent
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.89	3	0	aminopyridine
chaetochromin chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A	2.89	3	0
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.89	3	0	aromatic ketone
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.17	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	3.22	3	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.74	2	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.9	3	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.89	3	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.64	2	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.86	2	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.	2.21	1	0	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
indocate [no description available]	2.89	3	0
N(4)-acetylsulfathiazole N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.	2.89	3	0	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	9.61	16	2	1,2,3-triazole
cyclizine hydrochloride [no description available]	2.59	2	0
5,6,7,8-tetrahydro-1-naphthol 5,6,7,8-tetrahydro-1-naphthol : 1-naphthol hydrogenated at C-5, -6, -7 and -8.	3.31	1	0	tetralins
2,3-trimethylene-4-quinazolone 2,3-trimethylene-4-quinazolone: structure in first source	2.89	3	0	quinazolines
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.31	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
1,3-dimethyluric acid 1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.	2.89	3	0	oxopurine	metabolite
danofloxacin [no description available]	2.89	3	0	quinolines
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	3.16	3	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
nitrefazole [no description available]	2.89	3	0	imidazoles
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.89	3	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
honokiol [no description available]	2.89	3	0	biphenyls
9-methoxyellipticine 9-methoxyellipticine: RN given refers to parent cpd	2.89	3	0
3-aminophenoxazone 3-aminophenoxazone: also inhibits sulfatase; structure	2.89	3	0	phenoxazine
indole-2-carboxylic acid [no description available]	3.31	1	0	indolyl carboxylic acid
3-deazaneplanocin 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist	2.89	3	0
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	2.89	3	0	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	3.12	1	0	carbamate ester; oxazolidinone	metabolite
2-chlorodiazepam [no description available]	2.89	3	0
bendamustine hydrochloride [no description available]	13.47	24	15
prolinal [no description available]	3.35	1	0	pyrrolidines
Polycartine B [no description available]	2.89	3	0	phenazines
aminoquinuride dihydrochloride [no description available]	2.89	3	0
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.41	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
5-Chloro-1H-indole-2,3-dione [no description available]	3.35	1	0	indoles	anticoronaviral agent
thioproperazine mesylate [no description available]	2.89	3	0	phenothiazines
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	2.89	3	0	6-isopentenylaminopurine	cytokinin
4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available]	2.89	3	0	sulfonamide
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.63	2	0
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	4.15	2	1	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mafosfamide mafosfamide: RN given refers to cis-(+-)-isomer	3.04	1	0
sr141716 [no description available]	2.89	3	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.11	1	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
artesunic acid [no description available]	2.41	1	0
beta-carboline-3-carboxylic acid ethyl ester beta-carboline-3-carboxylic acid ethyl ester: isolated from brain tissue & urine; extremely potent displacer of diazepam from brain benzodiazepam receptors; structure in first source	3.27	1	0	beta-carbolines
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide [no description available]	2.59	2	0	aromatic ketone
fingolimod fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.	2.89	3	0	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
triptolide [no description available]	7.25	1	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
tesmilifene [no description available]	2.89	3	0	diarylmethane
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.59	2	0
tadalafil [no description available]	3.27	1	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
clofarabine [no description available]	2.25	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
(20s)-20-hydroxycholesterol 20-hydroxycholesterol: RN given refers to (20S)-isomer. 20-hydroxycholesterol : An oxysterol that is cholesterol substituted by a hydroxy group at position 20.	2.31	1	0	20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol	human metabolite; mouse metabolite
sr 27897 SR 27897: structure given in first source; a CCK(A) receptor antagonist	2.89	3	0	indolyl carboxylic acid
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	6.67	5	2	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.31	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.89	3	0	leucine derivative
norketamine norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation	2.89	3	0	organochlorine compound
indatraline indatraline: RN given for (trans)-isomer; structure in first source	2.63	2	0	indanes
methotrexate [no description available]	2.89	3	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
salvinorin a salvinorin A: from the herb, Salvia divinorum	2.21	1	0	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide 4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol	2.89	3	0
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis	2.89	3	0	phenylindole
l 741626 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source	2.89	3	0	piperidines
pomalidomide 3-aminophthalimidoglutarimide: structure in first source	6.92	3	1	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.31	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
8-chloroadenosine 8-chloroadenosine: active metabolite of 8-chloro-cyclic adenosine 3',5'-monophosphate	2.31	1	0
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	2.31	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.51	2	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
aclacinomycin aklavin: antibiotic prepared from culture liquids of streptomycete (A 1129); possessing antiphage activity; structure. aclacinomycin T : An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage.	2.25	1	0	aminoglycoside; anthracycline; deoxy hexoside; methyl ester; monosaccharide derivative; phenols; polyketide; tertiary alcohol; tetracenequinones; zwitterion	antimicrobial agent; antineoplastic agent; metabolite
dx 8951 [no description available]	2.89	3	0	pyranoindolizinoquinoline
birb 796 [no description available]	3.27	1	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
tipifarnib [no description available]	2.89	3	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.14	4	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
platycodin d platycodin D: triterpenoid saponin from a root of Platycodon grandiflorum; RN refers to (2beta,3beta,16alpha)-isomer; structure given in first source	2.6	1	0	triterpenoid saponin	metabolite
avasimibe [no description available]	2.89	3	0	monoterpenoid
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	2.31	1	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
l 163191 [no description available]	2.89	3	0
dizocilpine [no description available]	2.89	3	0	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
s-benzylcysteine [no description available]	2.89	3	0	S-aryl-L-cysteine zwitterion
chelidonine chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)	2.89	3	0	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid
lapatinib [no description available]	2.89	3	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	3.04	3	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	6.65	11	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
roxindole [no description available]	2.89	3	0	indoles	alpha-adrenergic antagonist; serotonergic drug
conidendrin [no description available]	2.89	3	0
gossypol acetic acid [no description available]	3.19	1	0
Porfiromycine [no description available]	2.89	3	0	mitomycin
nsc 95397 [no description available]	2.89	3	0	1,4-naphthoquinones
4-methyl-2-quinazolinamine 4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source	2.89	3	0
2-glycineamide-5-chlorophenyl-2-pyrryl ketone [no description available]	2.89	3	0
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	8.14	4	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
niguldipine hydrochloride [no description available]	2.63	2	0
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	2.41	1	0
2,5-bis(5-hydroxymethyl-2-thienyl)furan [no description available]	2.89	3	0	thiophenes
bortezomib [no description available]	16.95	27	4	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	6.3	6	2	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.21	1	0	cyclohexenones
gant 61 GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.	3.51	1	0	aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound	antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.58	2	0
carboplatin [no description available]	2.13	1	0
Destruxin B [no description available]	2.89	3	0	cyclodepsipeptide
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.21	1	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.	2.89	3	0	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	2.25	1	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.21	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	5.52	9	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
desthiobiotin desthiobiotin: RN given refers to cpd without isomeric designation; structure. (4R,5S)-dethiobiotin : The (4R,5S)-isomer of dethiobiotin.	3.35	1	0	dethiobiotin
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.13	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea 1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea : A member of the class of phenylureas that is urea which is substituted at position 1 by a 3-tert-butyl-1-methylpyrazol-5-yl group and at position 3 by a p-chlorophenyl group.	3.27	1	0	monochlorobenzenes; phenylureas; pyrazoles	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.17	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
obeticholic acid obeticholic acid: A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.. obeticholic acid : A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis.	2.15	1	0	3alpha-hydroxy steroid; 7alpha-hydroxy steroid; dihydroxy-5beta-cholanic acid	farnesoid X receptor agonist; hepatoprotective agent
aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.	3.86	2	0	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
decitabine [no description available]	13.69	62	2	2'-deoxyribonucleoside
apogossypol apogossypol: structure in first source	3.31	1	0
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.72	2	0	actinomycin	mutagen
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	3.5	2	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.21	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.58	2	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
posaconazole [no description available]	5.69	5	1	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.89	3	0
jp-1302 [no description available]	2.89	3	0
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one [no description available]	2.89	3	0	benzodiazepine
tenatoprazole Tenatoprazole: structure in first source	2.89	3	0	imidazopyridine
s 1033 [no description available]	2.89	3	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol [no description available]	2.89	3	0	hydroxyquinoline
benidipine hydrochloride [no description available]	2.59	2	0
benidipine benidipine: RN refers to (R,R)-(+-)-isomer	2.21	1	0
fludarabine [no description available]	17.67	18	10	purine nucleoside
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one [no description available]	2.89	3	0	quinazolines
chlorprothixene (E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.	2.89	3	0	chlorprothixene
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	2.89	3	0
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester [no description available]	2.89	3	0	methoxybenzenes; substituted aniline
3-hydroxypyridine, sodium salt [no description available]	2.89	3	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	2.89	3	0	naphthalenecarboxamide
5-[(2-bromoanilino)methyl]-8-quinolinol [no description available]	2.89	3	0	hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide 3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source	2.89	3	0
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline [no description available]	2.89	3	0	aromatic amine
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide [no description available]	2.89	3	0	piperidinecarboxamide
umi-77 UMI-77: an Mcl-1 inhibitor; structure in first source	3.99	3	0
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol [no description available]	2.89	3	0	hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide [no description available]	2.89	3	0	acetamides; anilide
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide [no description available]	2.89	3	0	aromatic amide; thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone [no description available]	2.89	3	0	dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide [no description available]	2.89	3	0	aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide [no description available]	2.89	3	0	aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione [no description available]	2.89	3	0	maleimides
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	2.89	3	0	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one [no description available]	2.89	3	0	dimethoxybenzene
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide [no description available]	2.89	3	0	quinolines
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine [no description available]	2.89	3	0	pyrroles
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	4.87	3	2	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tamoxifen [no description available]	4	2	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
bi-78d3 [no description available]	2.89	3	0	aryl sulfide
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	3.51	1	0
kartogenin kartogenin: promotes chondrocyte differentiation; structure in first source	2.89	3	0
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	2.21	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
telaprevir [no description available]	3.27	1	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	4.28	4	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.17	1	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cystine [no description available]	2.41	1	0
vx-745 [no description available]	2.89	3	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	7.33	11	2	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
zd 6474 CH 331: structure in first source	2.89	3	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide [no description available]	2.63	2	0	indoles
nih-12848 NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source	2.89	3	0
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide [no description available]	2.89	3	0	quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone [no description available]	2.89	3	0	benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile [no description available]	2.89	3	0	imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one [no description available]	2.89	3	0	aromatic ketone
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.15	1	0
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester [no description available]	2.89	3	0	oxopurine
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester [no description available]	2.89	3	0	organonitrogen compound; organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide [no description available]	2.89	3	0	quinolines
LSM-1924 [no description available]	2.89	3	0	organic heterotricyclic compound; organooxygen compound
ferrostatin-1 ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.	2.89	3	0	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.25	1	0
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine [no description available]	2.89	3	0	C-nitro compound
rabeprazole(1-) [no description available]	2.63	2	0	organic nitrogen anion
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	4.33	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.31	1	0	benzamides
ncgc00099374 [no description available]	2.89	3	0
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide [no description available]	2.89	3	0	benzamides
jtk-303 [no description available]	3.27	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
luteolin [no description available]	2.89	3	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
cyclosporine [no description available]	2.21	1	0
kaempferol [no description available]	2.89	3	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	2.89	3	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
montelukast montelukast: a leukotriene D4 receptor antagonist	2.21	1	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.89	3	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
bruceantin [no description available]	2.89	3	0	triterpenoid
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.89	3	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
daidzein [no description available]	2.89	3	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
neticonazole neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.	2.89	3	0	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.	2.89	3	0	endocannabinoid; N-acylethanolamine 22:6
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.89	3	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.78	2	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alpha-zearalenol [no description available]	2.89	3	0	macrolide
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	6.47	6	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.21	1	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine	3.35	1	0	D-leucine derivative; dichlorobenzene; furoic acid; glycine derivative; guanidines; pyrazolylpiperidine
su 9516 [no description available]	2.89	3	0
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.89	3	0	triazolopyrimidines
sb 277011 SB 277011: structure in first source	2.89	3	0
n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide: a nociceptin antagonist; structure in first source	2.31	1	0	aminoquinoline
sb 223412 SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source	2.89	3	0
sr 59230a [no description available]	2.89	3	0	tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	2.89	3	0	pyrimidines
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	2.89	3	0	piperazines
MeJA [no description available]	2.89	3	0	Jasmonate derivatives
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	2.82	2	0
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)- 1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source	2.89	3	0
pd 161570 PD 161570: structure in first source	2.89	3	0
su 11248 [no description available]	2.54	2	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	5.67	7	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	2.89	3	0	sulfonamide
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	3.04	3	0	metalloid atom; pnictogen	micronutrient
bedaquiline bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.	2.21	1	0	aromatic ether; naphthalenes; organobromine compound; quinolines; tertiary alcohol; tertiary amino compound	antitubercular agent; ATP synthase inhibitor
virginiamycin factor s1 virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.	2.89	3	0	cyclodepsipeptide; macrolide antibiotic	antibacterial drug; bacterial metabolite
bleomycin [no description available]	2.25	1	0	bleomycin	antineoplastic agent; metabolite
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	2.31	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.63	2	0	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
xib 4035 XIB 4035: a GFRalpha-1 agonist; structure in first source	2.89	3	0
gw-5074 [no description available]	2.21	1	0
everolimus [no description available]	2.94	3	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
belotecan belotecan: structure in first source	2.89	3	0	pyranoindolizinoquinoline
norgestimate [no description available]	2.89	3	0	ketoxime; steroid ester; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive
beta-escin [no description available]	2.6	1	0
b 43 RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).	2.89	3	0	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine [no description available]	2.89	3	0
methiazole methiazole: a parasitostatic agent	2.89	3	0	benzimidazoles; carbamate ester
sb 218795 SB 218795: structure in first source	2.89	3	0	quinolines
bvt.948 [no description available]	2.89	3	0
tubacin tubacin: inhibits histone deacetylase 6; structure in first source	2.25	1	0	1,3-oxazoles
sq-23377 Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.	2.41	1	0	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
fk 866 N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source	2.21	1	0	benzamides; N-acylpiperidine
a 38503 [no description available]	2.89	3	0
belinostat [no description available]	2.25	1	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	4.84	4	0	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
staurosporine staurosporinium : Conjugate acid of staurosporine.	7.02	13	0	ammonium ion derivative
parthenolide [no description available]	2.58	2	0	sesquiterpene lactone	drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
krn 633 N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source	2.89	3	0
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid [no description available]	2.89	3	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	2.89	3	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.	2.89	3	0	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	2.89	3	0
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	7.2	16	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
valnemulin [no description available]	2.63	2	0
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.89	3	0	organic heterotricyclic compound; organooxygen compound
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	2.89	3	0	aromatic amide
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	3.27	1	0	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ticagrelor Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.	2.89	3	0	aryl sulfide; hydroxyether; organofluorine compound; secondary amino compound; triazolopyrimidines	P2Y12 receptor antagonist; platelet aggregation inhibitor
l 692585 [no description available]	2.89	3	0	peptide
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.89	3	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
nnc 26-9100 NNC 26-9100: structure in first source	2.89	3	0	aminopyridine
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine [no description available]	2.89	3	0
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	2.89	3	0	aromatic ether
selexipag selexipag: prostacyclin receptor agonist. selexipag : A member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid).	2.15	1	0	aromatic amine; ether; monocarboxylic acid amide; N-sulfonylcarboxamide; pyrazines; tertiary amino compound	orphan drug; platelet aggregation inhibitor; prodrug; prostacyclin receptor agonist; vasodilator agent
hki 272 [no description available]	2.88	3	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.89	3	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.55	2	0	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
tae226 TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source	2.89	3	0	morpholines
gw0742 GW 610742: structure in first source	2.89	3	0	monocarboxylic acid
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- [no description available]	2.17	1	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
eht 1864 [no description available]	2.31	1	0
vosaroxin vosaroxin: has antineoplastic activity; vosaroxin was formerly voreloxin; structure in first source	2.21	1	0
u 18666a 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.	2.89	3	0	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	2.89	3	0	quinoxaline derivative
bx795 BX795: structure in first source	2.89	3	0	ureas
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.25	1	0	organic cation
azd 6244 AZD 6244: a MEK inhibitor	3.08	4	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	2.89	3	0
bay 61-3606 [no description available]	2.89	3	0	pyrimidines
binimetinib binimetinib : A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.	2.17	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monofluorobenzenes; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sd-208 [no description available]	2.89	3	0
crenolanib [no description available]	3.1	4	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466 CJ 033466: structure in first source	2.89	3	0
cc 401 CC 401: an anthrapyrazolone	2.89	3	0	pyrazoles; ring assembly
volasertib BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source	2.13	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.89	3	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
arterolane arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.	2.89	3	0
tafamidis tafamidis: may be effective in treating transthyretin amyloid polyneuropathy. tafamidis : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis.	4.33	1	0	1,3-benzoxazoles; dichlorobenzene; monocarboxylic acid	central nervous system drug
cariprazine cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.	2.89	3	0
krp-203 [no description available]	2.89	3	0
regorafenib [no description available]	2.89	3	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
at 7867 [no description available]	2.89	3	0	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	2.89	3	0	pyrroloquinoline
ptc 124 [no description available]	2.89	3	0	oxadiazole; ring assembly
degrasyn degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source	2.63	2	0
epoxomicin [no description available]	3.51	1	0	morpholines; tripeptide	proteasome inhibitor
abt-737 [no description available]	9.36	39	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	3.12	1	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
bi 2536 [no description available]	2.89	3	0
arq 197 [no description available]	2.21	1	0	indoles
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	2.89	3	0	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
pf 00299804 dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.	2.17	1	0	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
quisinostat [no description available]	2.17	1	0	indoles
carfilzomib [no description available]	8.32	10	1	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	18.64	42	5	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zstk474 ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.	2.13	1	0	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
motesanib [no description available]	2.89	3	0	pyridinecarboxamide
fostamatinib fostamatinib: a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406	3.19	1	0
trametinib [no description available]	4.33	3	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pf-562,271 [no description available]	2.89	3	0	indoles
gliocladin c gliocladin C: structure in first source	2.89	3	0
sb 706504 [no description available]	2.89	3	0
ly2603618 [no description available]	2.13	1	0	ureas
ku-0060648 [no description available]	2.89	3	0	dibenzothiophenes
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.11	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
bgt226 BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.	2.89	3	0	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine: a spleen tyrosine kinase (Syk) inhibitor; structure in first source	2.13	1	0
thienopyrimidine thienopyrimidine: structure in first source. thienopyrimidine : A class of aromatic heterobicyclic compounds each of which contains a pyrimidine ring ortho fused to a 5-membered thiophene ring.	3.31	1	0
n-desmethyldanofloxacin N-desmethyldanofloxacin: structure given in first source	2.89	3	0
rabeprazole sodium [no description available]	2.15	1	0	organic sodium salt
rrx-001 RRx-001: has antineoplastic activity; structure in first source	3.51	1	0
mdv 3100 [no description available]	2.31	1	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	2.63	2	0	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
CDN1163 CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).	2.89	3	0	aromatic ether; quinolines; secondary carboxamide	SERCA activator
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	3.06	4	0
gsk 269962a [no description available]	2.89	3	0
oligonucleotides [no description available]	5.43	3	0
e 7107 E 7107: has antineoplastic activity	2.17	1	0
gdc-0973 cobimetinib: has antineoplastic activity; structure in first source. cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma.	4.15	2	1	aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 848125 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor	2.89	3	0
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	6.33	5	1	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.15	1	0
nvp-bhg712 [no description available]	2.89	3	0	benzamides
pf 04217903 [no description available]	2.89	3	0	quinolines
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one [no description available]	2.89	3	0	aromatic ketone
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	2.89	3	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
chiniofon Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.	3.31	1	0
olaparib [no description available]	2.41	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720 [no description available]	2.89	3	0
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	3.64	2	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
purfalcamine purfalcamine: a PfCDPK-1 inhibitor; structure in first source	2.89	3	0
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.89	3	0	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gdc-0068 ipatasertib: an Akt kinase inhibitor; structure in first source	2.31	1	0	N-arylpiperazine
marinopyrrole a marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source. (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities.	5.24	5	0	aromatic ketone; organochlorine compound; phenols; pyrroles	antibacterial agent; antimicrobial agent; antineoplastic agent; bacterial metabolite; marine metabolite
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	18.45	140	25	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib [no description available]	3.6	7	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	3.51	1	0	piperazines
sch772984 [no description available]	2.17	1	0	biaryl; indazoles; N-acylpiperazine; N-alkylpyrrolidine; N-arylpiperazine; pyridines; pyrimidines; pyrrolidinecarboxamide; secondary carboxamide; tertiary amino compound; tertiary carboxamide	analgesic; antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
quizartinib [no description available]	2.89	3	0	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
PP121 [no description available]	2.89	3	0	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.31	1	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	10.64	55	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
gsk 650394 [no description available]	2.89	3	0	phenylpyridine
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.1	1	0	BODIPY compound
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.89	3	0	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	2.89	3	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
incb-018424 [no description available]	8.8	11	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	3.27	1	0	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
TAK-580 MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.	2.89	3	0	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor
glasdegib glasdegib: a smoothened inhibitor. glasdegib : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy.	8.55	12	0	benzimidazoles; nitrile; phenylureas; piperidines	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one [no description available]	2.89	3	0	chromones
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	3.78	2	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
pf 3758309 PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source	2.89	3	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source	2.63	2	0	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor
plx4032 [no description available]	2.66	2	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	0	aryl sulfide; thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	0	aryl sulfide; thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	0	aryl sulfide; thienopyrimidine
baricitinib [no description available]	4.24	4	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.89	3	0	quinazolines
arry 520 filanesib: a kinesin spindle protein inhibitor	3.51	1	0
piperidines Piperidines: A family of hexahydropyridines.	18.41	137	24
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	2.89	3	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide [no description available]	2.89	3	0	hydroxyquinoline
p505-15 [no description available]	2.89	3	0
mrt67307 MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source	2.89	3	0	aromatic amine
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide [no description available]	2.89	3	0	piperazines
ribociclib ribociclib: inhibits both CDK4 and CDK6	2.89	3	0
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone [no description available]	2.89	3	0	aromatic ketone; thienopyrimidine
apatinib apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source	7.41	1	0
gx 15-070 obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma	5.23	4	0
pha 793887 [no description available]	2.89	3	0	piperidinecarboxamide
azd3839 AZD3839: a BACE1 inhibitor; structure in first source	3.27	1	0
gsk 2334470 GSK 2334470: a PDK1 inhibitor; structure in first source	2.21	1	0	indazoles
abemaciclib [no description available]	2.41	1	0
ml228 probe ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.	2.89	3	0	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator
pf-03882845 [no description available]	2.89	3	0
jq1 compound [no description available]	2.89	3	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
dinaciclib [no description available]	4.19	4	0	pyrazolopyrimidine
pf-04620110 PF-04620110: a DGAT1 inhibitor; structure in first source	2.89	3	0
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.89	3	0	benzodiazepine
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	7.31	10	1	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib [no description available]	2.15	1	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.86	3	0	dipeptide
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.89	3	0	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
tubastatin a [no description available]	3.41	1	0	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	2.89	3	0	ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide [no description available]	2.89	3	0	(trifluoromethyl)benzenes
ncgc00242364 NCGC00242364: structure in first source	2.89	3	0	quinazolines
ipi-145 [no description available]	8.34	6	2	isoquinolines
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.89	3	0	imidazoquinoline
apr-246 eprenetapopt: works in tandem with cisplatin to cause apoptosis of tumor cells; structure in first source	6.03	3	1
hs-173 [no description available]	2.89	3	0
sr1664 [no description available]	2.89	3	0	indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source	2.89	3	0
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	2.25	1	0	polypeptide
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	4.59	3	0	pyrimidinecarboxylic acid
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	3.12	1	0
rg7388 RG7388: structure in first source	5	7	1
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.59	2	0	benzamides; N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.59	2	0	aminoquinoline
cudc-907 [no description available]	3.13	4	0
raltegravir [no description available]	3.27	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
methacycline Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.	2.21	1	0
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	3.31	1	0	monohydroxybenzoate	plant metabolite
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.53	1	1	benzenes; hydroxycoumarin; methyl ketone
methacycline monohydrochloride [no description available]	2.59	2	0
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid [no description available]	2.89	3	0	quinolines
a 769662 [no description available]	3.27	1	0	biphenyls
dolutegravir [no description available]	3.27	1	0	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
agi-5198 AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source	2.89	3	0
byl719 [no description available]	2.31	1	0	proline derivative
cep-32496 agerafenib: inhibitor of RAF family kinases; structure in first source	2.89	3	0
epz004777 [no description available]	2.89	3	0	N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid [no description available]	2.89	3	0	organonitrogen heterocyclic compound
jy-1-106 JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source	4.19	2	0
entecavir [no description available]	2.89	3	0	benzamides; N-acylpiperidine
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	3.31	1	0	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
cc-115 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one: an mTOR kinase inhibitor; structure in first source	4.43	1	1
gkt137831 setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative	2.89	3	0
vx-509 [no description available]	2.89	3	0
a-1155463 A-1155463: a Bcl-X(L) inhibitor; structure in first source	4.89	5	0
vx-970 berzosertib: an ATR kinase inhibitor	2.89	3	0	sulfonamide
gs-9973 [no description available]	2.89	3	0
amg 925 AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).	2.89	3	0
bm-1197 BM-1197: inhibits both Bcl-xL and Bcl-2; has antineoplastic activity	4.86	3	0
epz-6438 tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity	3.51	1	0
gne-618 GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source	2.89	3	0
erdafitinib erdafitinib: inhibitor of fibroblast growth factor receptors	2.25	1	0
ledipasvir ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.31	1	0	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor
g007-lk G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source	2.89	3	0
gsk-2816126 GSK-2816126: inhibits EZH2 methyltransferase; structure in first source	2.21	1	0	piperazines; pyridines
volitinib [no description available]	2.89	3	0
ML355 ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.	2.89	3	0	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	12.47	22	4	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	3.11	4	0	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
cpi203 CPI203: a BET protein bromodomain inhibitor	7.17	1	0
agi-6780 AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source	2.89	3	0
khs101 KHS101: a small molecule accelerates neuronal differentiation in the adult rat	2.89	3	0
chiglitazar chiglitazar: structure in first source	2.6	1	0
idarucizumab [no description available]	4.33	1	0
selinexor selinexor: inhibits karyopherin XPO1	4.93	5	0
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	2.82	2	0	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
a-1331852 A-1331852: a Bcl-X(L) inhibitor; structure in first source	5.28	8	0
cb-839 [no description available]	4	4	0
ivosidenib ivosidenib: an inhibitor of isocitrate dehydrogenase 1 (IDH1) for treatment of acute myeloid leukemia (AML). ivosidenib : A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation.	9.13	9	2	cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
gsk-j4 GSK-J4: a JMJD3 inhibitor; structure in first source	3.11	4	0	organonitrogen heterocyclic compound
pf-06424439 PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source	2.89	3	0
etp-46464 ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source	2.89	3	0
imetelstat [no description available]	3.31	1	0
glutaminase [no description available]	3.53	2	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.61	2	0
onc201 TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source	2.89	3	0
kai407 KAI407: an antimalarial; structure in first source	2.89	3	0
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source	2.89	3	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	7.94	32	0
enasidenib [no description available]	6.95	9	0	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429 OICR-9429: antineoplastic; structure in first source	2.89	3	0
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.89	3	0
BDA-366 BDA-366: has antineoplastic activity; binds Bcl-2 protein; structure in first source. BDA-366 : A member of the class of anthraquinone that is 1,4-diamino-9,10-anthraquinone in which the two amino groups are carrying 3-(diethylamino)-2-hydroxypropyl and (oxiran-2-yl)methyl substituents. It exhibits anti-cancer properties.	3.51	1	0	anthraquinone; epoxide; secondary alcohol; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer
oridonin [no description available]	2.6	1	0
oblimersen oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions	3.25	1	0
nusinersen nusinersen: an antisense oligonucleotide that induces SMN protein expression	2.15	1	0
at 9283 [no description available]	2.89	3	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.21	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
hypoxanthine [no description available]	2.89	3	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.51	1	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.89	3	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.27	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
zaprinast zaprinast: anaphylaxis inhibitor; structure	3.27	1	0	triazolopyrimidines
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	3.27	1	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	3.35	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
1-hydroxyphenazine 1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.	2.89	3	0	phenazines
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	2.31	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
ro 24-7429 Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9	2.89	3	0	benzodiazepine
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.89	3	0
apogossypolone apogossypolone: has antineoplastic activity; structure in first source	4.14	2	0
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide [no description available]	2.89	3	0	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.89	3	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	2.89	3	0
sta 9090 [no description available]	2.6	1	0	ring assembly; triazoles
bmn 673 talazoparib: inhibits both PARP1 and PARP2; structure in first source	2.89	3	0
bay 80-6946 copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.	2.63	2	0
defibrotide defibrotide: Single-stranded polydeoxyribonucleotide extracted from mammalian organs and used in the treatment of HEPATIC VENO-OCCLUSIVE DISEASE in patients with kidney or lung abnormalities following HEMATOPOIETIC STEM CELL TRANSPLANTATION	2.15	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	4.58	4	1
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.25	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Hematologic Malignancies [description not available]	0	16.75	51	2
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	1	13.75	51	2
Benign Neoplasms [description not available]	0	10.73	37	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	15.12	74	2
Kahler Disease [description not available]	0	15.15	77	14
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	1	17.15	77	14
Germinoblastoma [description not available]	0	5.71	16	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1	7.71	16	0
Acute Myelogenous Leukemia [description not available]	0	24.45	703	136
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1	26.45	703	136
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	5.35	17	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Experimental Neoplasms [description not available]	0	4.01	4	0
Rheumatoid Arthritis [description not available]	0	2.41	1	0
Autoimmune Disease [description not available]	0	5.87	3	2
Libman-Sacks Disease [description not available]	0	7.3	5	3
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	2.41	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	5.87	3	2
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	7.3	5	3
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	23.16	446	108
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	1	25.16	446	108
Cancer, Second Primary [description not available]	0	8.73	11	3
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	1	9.97	24	1
Acute Promyelocytic Leukemia [description not available]	0	9.91	10	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	0	4.91	10	0
Blast Phase [description not available]	0	5.62	12	0
Myelomonocytic Leukemia, Chronic [description not available]	0	7.07	8	1
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	1	7.62	12	0
Leukemia, Myelomonocytic, Chronic A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.	0	7.07	8	1
Minimal Disease, Residual [description not available]	0	16.37	63	32
Granulocytic Leukemia, Chronic [description not available]	0	9.79	15	4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	1	11.79	15	4
Infection [description not available]	0	7.18	5	2
Lymphocytopenia [description not available]	0	2.31	1	0
Duncan Disease [description not available]	0	3.88	3	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	7.18	5	2
Lymphopenia Reduction in the number of lymphocytes.	0	2.31	1	0
Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified.	0	3.88	3	0
Local Neoplasm Recurrence [description not available]	0	17.97	111	47
Dysmyelopoietic Syndromes [description not available]	0	12.51	45	4
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	1	14.51	45	4
Diffuse Large B-Cell Lymphoma [description not available]	0	10.26	43	6
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	1	12.26	43	6
Benign Meningeal Neoplasms [description not available]	0	2.41	1	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	0	2.41	1	0
Colorectal Cancer [description not available]	0	8.26	5	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	3.26	5	0
Acute Lymphoid Leukemia [description not available]	0	6.74	39	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	1	10.74	117	0
Eosinophilia, Tropical [description not available]	0	2.41	1	0
Granulomatosis, Wegener's [description not available]	0	2.41	1	0
Endocarditis, Loeffler [description not available]	0	2.41	1	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	0	2.41	1	0
Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.	0	2.41	1	0
Hypereosinophilic Syndrome A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.	0	2.41	1	0
Ph 1 Chromosome [description not available]	0	3.58	6	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	12.74	45	8
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	1	14.74	45	8
Recrudescence [description not available]	0	19.75	144	83
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	12.44	21	10
Disease Exacerbation [description not available]	0	9.95	20	3
Familial Waldenstrom's Macroglobulinaemia [description not available]	0	5.67	5	1
Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.	1	7.67	5	1
Hypocalcemia Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)	0	2.41	1	0
Ecchymosis Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.	0	2.31	1	0
Leukemia, Plasmacytic [description not available]	0	3.89	9	0
Leukemia, Plasma Cell A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.	0	3.89	9	0
African Lymphoma [description not available]	0	3.01	3	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	1	5.01	3	0
2019 Novel Coronavirus Disease [description not available]	0	8.4	10	2
Leukemia, Acute Monocytic [description not available]	0	2.41	1	0
Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.	0	2.41	1	0
Disseminated Fungal Infection [description not available]	0	4.43	5	0
Brill-Symmers Disease [description not available]	0	8.98	12	3
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	1	13.34	24	6
Breast Cancer [description not available]	0	8.98	17	2
Breast Neoplasms Tumors or cancer of the human BREAST.	1	13.33	34	4
Cancer of Skin [description not available]	0	5.64	13	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	5.64	13	0
Tumour Lysis Syndrome [description not available]	0	14.94	51	14
Tumor Lysis Syndrome A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.	0	14.94	51	14
Fungal Diseases [description not available]	0	3.6	2	0
Mycoses Diseases caused by FUNGI.	0	3.6	2	0
Glial Cell Tumors [description not available]	0	3.33	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	3.33	1	0
Leucocythaemia [description not available]	0	7.01	8	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1	14.01	8	1
Lassitude [description not available]	0	5.41	3	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	5.41	3	1
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	0	4.66	4	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	3.6	2	0
Gammapathy, Monoclonal [description not available]	0	3.64	2	0
Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.	0	3.64	2	0
B-Cell Lymphoma [description not available]	0	9.73	32	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	9.73	32	1
Cardiac Toxicity [description not available]	0	2.41	1	0
Arrhythmia [description not available]	0	3.64	2	0
Innate Inflammatory Response [description not available]	0	4.26	5	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	3.64	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	9.26	5	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	2.41	1	0
Cancer of Spleen [description not available]	0	2.41	1	0
Abnormal Karyotype A variation from the normal set of chromosomes characteristic of a species.	0	5.1	7	1
Chloroma [description not available]	0	4.45	6	0
Sarcoma, Epithelioid [description not available]	0	2.76	2	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	7.76	2	0
Sarcoma, Myeloid An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.	0	4.45	6	0
Debility [description not available]	0	3.98	3	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	10.94	16	5
Splenic Rupture Rupture of the SPLEEN due to trauma or disease.	0	2.76	2	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	1	12.94	16	5
B-Cell Prolymphocytic Leukemia [description not available]	0	2.96	3	0
Leukemia, Prolymphocytic, B-Cell A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.	0	2.96	3	0
Graft-Versus-Host Disease [description not available]	0	7.9	15	9
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	0	7.9	15	9
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	0	3.33	1	0
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	0	3.33	1	0
P carinii Pneumonia [description not available]	0	2.41	1	0
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	0	2.41	1	0
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	0	9.04	24	1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	1	11.04	24	1
Abnormalities, Autosome [description not available]	0	4.15	4	0
Chromosome Deletion Actual loss of portion of a chromosome.	0	11.29	15	5
Fatty Liver, Nonalcoholic [description not available]	0	2.41	1	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	0	2.41	1	0
Chromosomal Translocation [description not available]	0	10.14	27	6
AL Amyloidosis [description not available]	0	5.42	11	0
Immunoglobulin Light-chain Amyloidosis A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.	0	5.42	11	0
Acute Disease Disease having a short and relatively severe course.	0	6.41	7	1
Adverse Drug Event [description not available]	0	2.91	3	0
Vitiligo A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.	0	2.41	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.91	3	0
EBV Infections [description not available]	0	2.9	2	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	2.9	2	0
Aggressive Systemic Mastocytosis A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.	0	2.6	1	0
Mastocytosis, Systemic A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.	0	2.6	1	0
Leukemia, Megakaryocytic [description not available]	0	3.52	4	0
Leukemia, Megakaryoblastic, Acute An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.	0	3.52	4	0
Enlarged Spleen [description not available]	0	2.6	1	0
HIV Coinfection [description not available]	0	4.53	4	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	4.53	4	0
Cytomegalic Inclusion Disease [description not available]	0	2.6	1	0
Viremia The presence of viruses in the blood.	0	2.6	1	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	0	2.6	1	0
Granulocytic Leukemia [description not available]	0	5	7	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	5	7	0
Acquired Autoimmune Hemolytic Anemia [description not available]	0	3.36	5	0
Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.	0	3.36	5	0
Hairy Cell Leukemia [description not available]	0	2.69	2	0
Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.	0	2.69	2	0
Leukemia, Pre-B-Cell [description not available]	0	3.52	6	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	3.52	6	0
Carcinoma, Small Cell Lung [description not available]	0	3.25	4	0
Cancer of Lung [description not available]	0	3.76	8	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	3.76	8	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	1	5.25	4	0
Thrombopenia [description not available]	0	15.88	56	51
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	20.88	56	51
Liver Dysfunction [description not available]	0	3.99	1	1
Liver Diseases Pathological processes of the LIVER.	0	3.99	1	1
Hepatocellular Carcinoma [description not available]	0	2.6	1	0
Cancer of Liver [description not available]	0	2.6	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.6	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.6	1	0
Anemia, Fanconi [description not available]	0	3.52	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	0	3.52	1	0
Blood Diseases [description not available]	0	7.97	7	4
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	7.97	7	4
Cancer of Cervix [description not available]	0	2.6	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.6	1	0
Prolymphocytic Leukemia [description not available]	0	3.4	5	0
Leukemia, Lymphocytic, Chronic, T Cell [description not available]	0	5.14	8	1
Leukemia, Prolymphocytic, T-Cell A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.	1	7.14	8	1
Leukemia, Prolymphocytic A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.	1	5.4	5	0
Chronic Illness [description not available]	0	4.21	3	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	4.21	3	0
AIDS Seroconversion [description not available]	0	2.6	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	9.61	8	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	14.82	50	50
Pneumonia Infection of the lung often accompanied by inflammation.	0	14.82	50	50
Exanthem [description not available]	0	2.21	1	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	0	2.21	1	0
Acute Edematous Pancreatitis [description not available]	0	2.21	1	0
Congenital Varicella Syndrome [description not available]	0	2.21	1	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	2.21	1	0
Hepatitis INFLAMMATION of the LIVER.	0	2.21	1	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	0	2.21	1	0
Genetic Predisposition [description not available]	0	4.6	3	0
Granulocytic Leukemia, Chronic, Stable Phase [description not available]	0	7.68	4	4
Symptom Cluster [description not available]	0	3.17	1	0
Syndrome A characteristic symptom complex.	0	3.17	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	4.99	2	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	3.17	1	0
Acute Kidney Failure [description not available]	0	3.6	2	0
Hyperuricemia Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.	0	3.57	2	0
Hyperphosphatemia A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.	0	3.17	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	3.6	2	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	2.25	1	0
Diathesis [description not available]	0	4.04	2	0
T-Cell Lymphoma [description not available]	0	2.66	2	0
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	0	2.66	2	0
Dermatoses [description not available]	0	2.25	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.25	1	0
Emesis [description not available]	0	2.25	1	0
Acute Biphenotypic Leukemia [description not available]	0	2.25	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	6.6	3	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	2.25	1	0
Leukemia, Biphenotypic, Acute An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.	1	4.94	3	0
Auricular Fibrillation [description not available]	0	6.59	3	1
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	6.59	3	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1	4.25	1	0
Autoimmune Thrombocytopenia [description not available]	0	2.25	1	0
Encephalitis, JC Polyomavirus [description not available]	0	2.25	1	0
Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7)	0	2.25	1	0
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	0	2.25	1	0
Cancer of Pancreas [description not available]	0	2.93	3	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.93	3	0
Leukemia, Smoldering [description not available]	0	3.17	1	0
Cancer, Radiation-Induced [description not available]	0	3.17	1	0
Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.	0	3.17	1	0
Infections, Coronavirus [description not available]	0	4.55	1	1
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	0	4.55	1	1
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	0	4.55	1	1
Electrocardiogram QT Prolonged [description not available]	0	3.5	2	0
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	3.5	2	0
Leukocytopenia [description not available]	0	14.78	49	49
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	0	14.78	49	49
17p11.2 Monosomy [description not available]	0	5.22	5	0
Smith-Magenis Syndrome Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.	0	5.22	5	0
Blood Pressure, High [description not available]	0	4.55	1	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	4.55	1	1
Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)	0	4.55	1	1
Complications, Neoplastic Pregnancy [description not available]	0	2.31	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.31	1	0
Leukocytosis A transient increase in the number of leukocytes in a body fluid.	0	2.31	1	0
Leukemia, Myeloid, Acute, M4 [description not available]	0	2.31	1	0
Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.	0	2.31	1	0
Granuloma, Hodgkin [description not available]	0	2.76	2	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	0	2.76	2	0
Cold Panniculitis [description not available]	0	2.31	1	0
Thrombocythemia [description not available]	0	2.31	1	0
Cholera Infantum [description not available]	0	4.62	1	1
Androgen-Independent Prostatic Cancer [description not available]	0	2.31	1	0
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	2.31	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.55	2	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	0	2.31	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	0	2.31	1	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.31	1	0
Cancer of Head [description not available]	0	2.31	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.31	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	2.31	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	3.23	1	0
Neoplasms, Plasma Cell Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.	0	2.31	1	0
Cardiomyopathies, Primary [description not available]	0	4.15	1	0
Amyloid Neuropathy Type 1 [description not available]	0	4.15	1	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	0	4.15	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	0	4.15	1	0
Amyloid Neuropathies, Familial Inherited disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. The different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (PREALBUMIN); APOLIPOPROTEIN A-I; and GELSOLIN.	0	4.15	1	0
Ovoid Neutrophil Nuclei, Developmental Delay, Epilepsy and Skeletal Abnormalities [description not available]	0	2.31	1	0
Lung Injury, Acute [description not available]	0	2.31	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	0	2.31	1	0
Cancer of Mediastinum [description not available]	0	2.31	1	0
Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM.	0	2.31	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.66	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	4.66	2	0
Malignant Melanoma [description not available]	0	2.61	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.61	2	0
Cardiac Diseases [description not available]	0	2.31	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2.31	1	0
Benign Neoplasms, Brain [description not available]	0	2.59	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.59	2	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	3.98	1	0
Oncogene Addiction The dependence of tumor cells on a single oncogenic pathway or protein for their continued proliferation and survival.	0	3.06	1	0
Cutaneous T-Cell Lymphoma [description not available]	0	2.15	1	0
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	1	4.15	1	0
Autosomal Chromosome Disorders [description not available]	0	3.09	1	0
Bleeding [description not available]	0	3.09	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	0	3.09	1	0
Benign Monoclonal Gammopathies [description not available]	0	3.09	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	0	7.17	1	0
Disease, Pulmonary [description not available]	0	2.17	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	0	2.17	1	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	0	7.17	1	0
Cancer of Nasopharynx [description not available]	0	2.17	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	0	2.17	1	0
Chemotherapy-Induced Febrile Neutropenia FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.	0	4.9	2	1
Asthma, Bronchial [description not available]	0	2.58	2	0
Allergic Reaction [description not available]	0	2.21	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	2.58	2	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	2.21	1	0
Metastase [description not available]	0	3.59	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	3.59	1	1
Central Nervous System Neoplasm [description not available]	0	2.21	1	0
Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.	0	2.21	1	0
Autoimmune Diabetes [description not available]	0	2.21	1	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	0	2.21	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	0	2.21	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	0	2.21	1	0
Multiple Primary Neoplasms [description not available]	0	2.21	1	0
Hepatic Insufficiency Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.	0	3.59	1	1
Angiohemophilia [description not available]	0	2.21	1	0
von Willebrand Diseases Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.	0	2.21	1	0
Cholangiocellular Carcinoma [description not available]	0	2.1	1	0
Bile Duct Cancer [description not available]	0	2.1	1	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	0	2.1	1	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	0	2.1	1	0
Cancer of Prostate [description not available]	0	2.1	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1	4.1	1	0
Invasiveness, Neoplasm [description not available]	0	2.5	2	0
Cells, Neoplasm Circulating [description not available]	0	2.11	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	2.11	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	2.11	1	0
Carcinoma, Anaplastic [description not available]	0	3.04	1	0
Hormone-Dependent Neoplasms [description not available]	0	3.04	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	3.04	1	0
Benign Cerebellar Neoplasms [description not available]	0	2.11	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	0	2.11	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	0	2.11	1	0
Leukemia, Lymphocytic [description not available]	0	3.03	1	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	1	5.03	1	0
Cancer of Ovary [description not available]	0	2.13	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.13	1	0
Glomerulonephritis, Lupus [description not available]	0	2.13	1	0
Interstitial Nephritis [description not available]	0	2.13	1	0
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	0	2.13	1	0
Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.	0	2.13	1	0

abt-199

Description

Cross-References

Synonyms (91)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (8)

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (201)

Molecular Functions (26)

Ceullar Components (23)

Bioassays (213)

Research

Studies (1,471)

Market Indicators

Research Demand Index: 36.23

Study Types

abt-199

Description

Cross-References

Synonyms (91)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (8)

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (201)

Molecular Functions (26)

Ceullar Components (23)

Bioassays (213)

Research

Studies (1,471)

Market Indicators

Research Demand Index: 36.23

Study Types

Related Drugs (637)

Related Conditions (327)